Document:

exv10w1

Exhibit 10.1

***Text Omitted and Filed Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(b)(4)

and 240.24b-2.

COLLABORATION AGREEMENT

between

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

and

GEN-PROBE INCORPORATED

Dated as of June 15, 2010

 

 

COLLABORATION AGREEMENT

     THIS COLLABORATION AGREEMENT (the “Agreement”) is entered into between Pacific
Biosciences of California, Inc., a Delaware corporation (“PacBio”), having a place of
business at 1505 Adams Drive, Menlo Park, California 94025 and Gen-Probe Incorporated, a Delaware
corporation (“Gen-Probe”), having a place of business at 10210 Genetic Center Drive, San
Diego, California 92121. PacBio and Gen-Probe may each sometimes be referred to herein as a
“party” and collectively as the “parties.”

RECITALS

     WHEREAS, the parties each recognize the potential mutual benefit in cooperating in the
potential development of instrumentation and related products for the Diagnostics (as defined
herein) market (the “Collaboration”).

     WHEREAS, PacBio owns or has proprietary rights and expertise in Sample Preparation Systems (as
defined herein) and Third Generation Sequencing Systems (as defined herein) and associated
technologies.

     WHEREAS, Gen-Probe owns or has proprietary rights and expertise in the areas of Diagnostics
workflow, systems integration, and Sample Preparation Systems, and expertise in the areas of
clinical product development and regulatory clearances.

     WHEREAS, the parties desire to collaborate toward the joint development of Products (each as
defined herein) on the terms and subject to the conditions of this Agreement.

     WHEREAS, the parties intend to enter subsequently into one or more Preferred Partnership
Agreements (as defined herein), if warranted, to collaborate toward the further development,
regulatory clearance and commercialization of Products in the Field, including Products developed
under the terms of this Agreement.

     WHEREAS, in connection herewith, the parties are also entering into a stock purchase agreement
(the “Stock Purchase Agreement”), pursuant to which Gen-Probe shall purchase shares of
PacBio’s Series F preferred stock for an aggregate purchase price equal to $50 million.

     NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth
below, the parties hereby agree as follows:

ARTICLE 1

DEFINITIONS

     For purposes of this Agreement, the terms defined in this Article 1 shall have the respective
meanings set forth below:

     1.1 “Action” shall have the meaning set forth in Section 7.10.

1

 

     1.2 “Affiliate” shall mean, with respect to any Person, any other Person which directly or
indirectly controls, is controlled by, or is under common control with, such Person. A Person
shall be regarded as in control of another Person if it owns, or directly or indirectly controls,
more than fifty percent (50%) of the voting stock or other ownership interest of the other Person
(or such lesser percentage as is the maximum percentage permitted under applicable law for foreign
ownership where control is exercised by contract or otherwise), or if it directly or indirectly
possesses the power to direct or cause the direction of the management and policies of the other
Person by any means whatsoever (provided, however, that in the case of an entity organized under
Section 501(c)(3) of the Internal Revenue Code, the direct or indirect power of a party to direct
or cause the direction of the management and policies of the entity shall not in and of itself
cause the entity to be deemed an Affiliate for purposes of this Agreement).

     1.3 “Agreement” shall have the meaning set forth in the Preamble hereto.

     1.4 “Change of Control” shall mean, with respect to a party, any of the following: (a)
the sale or disposition of all or substantially all of the assets of such party or its direct or
indirect parent corporation to a Third Party, (b) the acquisition by a Third Party which
constitutes one person, as such term is used in Section 13(d) and 14(d) of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), together with any such person’s “affiliates” or
“associates,” as such terms are defined in the Exchange Act, other than an employee benefit plan
(or related trust) sponsored or maintained by such party or any of its Affiliates, of more than 50%
of the outstanding shares of voting capital stock of such party or its direct or indirect parent
corporation, or (c) the merger or consolidation of such party or its direct or indirect parent
corporation with or into another corporation, other than, in the case of this clause (c), an
acquisition or a merger or consolidation of such party or its direct or indirect parent corporation
in which holders of shares of the voting capital stock of such party or its direct or indirect
parent corporation, as the case may be, immediately prior to the acquisition, merger or
consolidation will have at least fifty percent (50%) of the ownership of voting capital stock of
the acquiring Third Party or the surviving corporation in such merger or consolidation, as the case
may be, immediately after the merger or consolidation.

     1.5 “Collaboration” shall have the meaning set forth in the recitals.

     1.6 “Commercially Available” shall mean, with respect to a product and a party, that
such product is made available by such party or its Affiliate to a Third Party through (i)
commercial sale or transfer of such product (including pursuant to an OEM supply arrangement) or
(ii) commercial sale of a service utilizing such product.

     1.7 “Commercially Reasonable Efforts” shall mean the application of efforts and
available resources, not materially inconsistent with the exercise of prudent scientific and
business judgment. “Commercially Reasonable Efforts” shall be deemed to have occurred if a
reasonably prudent business person would have exerted similar efforts after taking into account,
among other factors, in no particular order, and with no particular relative weighting: the
industry; the relative market timing, potential, and size, and the stage in the development or life
of, the relevant product(s) and/or services, and the dependencies and other interrelationships
there between; the size and stage in the development or life of the entity; the current and
projected future availability of sufficient capital and other resources, and the terms on which
such resources are or will be available; and/or any other factor(s) actually considered and/or that
a reasonably prudent business person would consider under similar

2

 

circumstances. Subject to and without limiting the foregoing, “Commercially Reasonable Efforts”
shall require the applicable party to: (i) promptly assign responsibilities for activities for
which it is responsible to specific employee(s) who are held accountable for the progress,
monitoring and completion of such activities, (ii) set and consistently seek to achieve meaningful
objectives for carrying out such activities, and (iii) make and implement decisions and allocate
available resources necessary or appropriate to advance progress with respect to and complete such
activities.

     1.8 “Confidential Information” shall mean, with respect to a party, all information,
whether in written, oral or visual presentation form, of any kind whatsoever (including
compilations, data, formulae, models, patent disclosures, procedures, processes, projections,
protocols, results of experimentation and testing, specifications, strategies, and techniques), and
all tangible and intangible embodiments thereof of any kind whatsoever (including apparatus,
compositions, documents, drawings, machinery, patent applications, records, reports), which is (i)
not generally known, (ii) disclosed by such party to the other party pursuant to and in accordance
with the terms of Article 6 of this Agreement and (iii) is identified as confidential, or is
otherwise treated by the Disclosing Party as confidential or which the other party has a reasonable
basis to believe is confidential at the time of disclosure.

     Notwithstanding the foregoing, Confidential Information of a party shall not include
information which the other party can establish by written documentation (a) to have been publicly
known prior to disclosure of such information by the Disclosing Party to the other party, (b) to
have become publicly known, without fault on the part of the other party, subsequent to disclosure
of such information by the Disclosing Party to the other party, (c) to have been received by the
other party at any time from a source, other than the disclosing party, rightfully having
possession of and the right to disclose such information, (d) to have been otherwise known by the
other party prior to disclosure of such information by the Disclosing Party to the other party or
(e) to have been independently developed by employees or agents of the other party without access
to or use of such information disclosed by the Disclosing Party to the other party.

     1.9 “Confidentiality Agreement” shall mean the Confidentiality Agreement, dated as of
February 12, 2010, between Gen-Probe and PacBio.

     1.10 “Development Plans” shall have the meaning set forth in Section 2.1.2.

     1.11 “Diagnostics” shall mean the in vitro testing of human specimens (including
processed human specimens) for the purpose of medical care of the human from whom the specimen was
taken and/or medical care of a human who is the potential recipient of tissue from the human from
whom the specimen was taken. For the avoidance of doubt, “medical care” shall include, by way of
example and not of limitation, diagnosis, prognosis, treatment, prevention, or monitoring the
progress of any and all possible human disease (including infectious, genetic, traumatic,
metabolic, degenerative, and neoplastic disease) as well as compatibility of donor and recipient
with respect to tissue. At Gen-Probe’s sole option, exercisable upon written notice to PacBio,
“Diagnostics” shall also mean the in vitro testing of human specimens for the purpose of medical
care of a human who is the potential recipient of human blood, plasma or other blood products from
the human from whom the specimen was taken. For the avoidance of doubt, such medical care shall
include, by way of example and not of limitation, diagnosis of possible disease prior to transplant
or transfusion, as well as compatibility of donor and recipient with respect to human blood,
plasma, and other blood products.

3

 

     1.12 “Disclosing Party” shall have the meaning set forth in Section 6.1

     1.13 “DNA” shall mean any and all forms of deoxyribonucleic acid, including without
limitation methylated and other modified deoxyribonucleic acid sequences and complementary
deoxyribonucleic acid synthesized from ribonucleic acid.

     1.14 “Effective Date” shall mean June 15, 2010.

     1.15 “Essential Ancillaries” shall mean the reagents and other consumables (including
chips) that are necessary for the effective use of V2 [...***...] or Sample Preparation [...***...], in
each case to the extent Commercially Available, respectively, from PacBio or Gen-Probe.

     1.16 “Field” shall mean the field of nucleic acid sequencing products and services
expressly marketed for Diagnostics use, including the parties’ own internal research and
development of Products that are intended to be expressly marketed for Diagnostics use. For the
avoidance of doubt, solely for purposes of determining whether Gen-Probe and its Affiliates have
complied with the exclusivity obligations set forth in Section 4.1, “nucleic acid sequencing” shall
not include methods utilizing multiplexed beads (e.g., [...***...]) or capillary electrophoresis, as
such methods are incorporated in a product offered by Gen-Probe or its Affiliates as of the
Effective Date.

     1.17 “Front End Sample Preparation” shall mean the isolation, extraction and/or
purification of nucleic acid from tissue and bodily fluids obtained directly or indirectly from a
human for sequencing, but excluding steps that are integral and specific to the sequencing process
itself.

     1.18 “Gen-Probe” shall have the meaning set forth in the Preamble hereto.

     1.19 “Gen-Probe Copyrights” shall mean all rights under the copyright laws of any
jurisdiction in the world and similar laws granting rights for written expression, together with
all rights commonly referred to as “moral rights,” to the extent that Gen-Probe has the right to
grant licenses, immunities or other rights thereunder as of the Effective Date or thereafter.

     1.20 “Gen-Probe Derivative IP” shall have the meaning set forth in Section 7.5.1.

     1.21 “Gen-Probe Intellectual Property Rights” shall mean, collectively, the Gen-Probe
Copyrights, Gen-Probe Know-How and Gen-Probe Patent Rights.

     1.22 “Gen-Probe Inventions” shall have the meaning set forth in Section 7.1.

     1.23 “Gen-Probe Know-How” shall mean information, expertise or data developed by or
for Gen-Probe (including formulae, procedures, protocols, techniques, data and results of
experimentation and testing) to the extent that Gen-Probe has the right, under the laws of any
jurisdiction in the world, to grant licenses, immunities or other rights thereunder as of the
Effective Date or thereafter.

     1.24 “Gen-Probe Patent Rights” shall mean patents and patent applications in any
jurisdiction of the world as to which Gen-Probe has an ownership or other licensable interest
(other than a license from PacBio pursuant to this Agreement) as of the Effective Date or
thereafter, including with respect to any Gen-Probe Invention.

***Confidential Treatment Requested

4

 

     1.25 “Initial Development Plan” shall have the meaning set forth in Section 2.1.1.

     1.26 “JAMS” shall have the meaning set forth in Section 9.3.

     1.27 “Joint Copyrights” shall have the meaning set forth in Section 7.3.1.

     1.28 “Joint Intellectual Property” shall have the meaning set forth in Section 7.6.

     1.29 “Joint Inventions” shall have the meaning set forth in Section 7.1.

     1.30 “Joint Know-How” shall have the meaning set forth in Section 7.4.

     1.31 “Licensed GP IP” shall have the meaning set forth in Section 2.4.1.

     1.32 “Licensed PacBio IP” shall have the meaning set forth in Section 2.4.2.

     1.33 “PacBio” shall have the meaning set forth in the preamble hereto.

     1.34 “PacBio Copyrights” shall mean all rights under the copyright laws of any
jurisdiction in the world and similar laws granting rights for written expression, together with
all rights commonly referred to as “moral rights,” to the extent that PacBio has the right to grant
licenses, immunities or other rights thereunder as of the Effective Date or thereafter.

     1.35 “PacBio Derivative IP” shall have the meaning set forth in Section 7.5.1.

     1.36 “PacBio Intellectual Property Rights” shall mean, collectively, the PacBio
Copyrights, PacBio Know-How and PacBio Patent Rights.

     1.37 “PacBio Inventions” shall have the meaning set forth in Section 7.1.

     1.38 “PacBio Know-How” shall mean information, expertise or data developed by or for
PacBio (including formulae, procedures, protocols, techniques, data and results of experimentation
and testing) which relates to the Products to the extent that PacBio has the right, under the laws
of any jurisdiction in the world, to grant licenses, immunities or other rights thereunder as of
the Effective Date or thereafter.

     1.39 “PacBio Patent Rights” shall mean patents and patent applications in any
jurisdiction of the world claiming technology as to which PacBio has an ownership or other
licensable interest (other than a license from Gen-Probe pursuant to this Agreement) as of the
Effective Date or thereafter, including with respect to any PacBio Invention.

     1.40 “Person” shall mean an individual, corporation, partnership, limited liability
company, trust, business trust, association, joint stock company, joint venture, pool, syndicate,
sole proprietorship, unincorporated organization, governmental authority or any other form of
entity not specifically listed herein, and including Gen-Probe and PacBio.

     1.41 “Preferred Access Products” shall mean the products supplied by the parties
pursuant to Section 2.2.

5

 

     1.42 “Preferred Partnership Agreements” shall have the meaning set forth in Section
2.5.

     1.43 “Product Development Plans” shall have the meaning set forth in Section 2.1.2.

     1.44 “Products” shall mean one or more integrated system products integrating nucleic
acid sequencing and Front End Sample Preparation, in each case for use in the Field.

     1.45 “Proof of Concept” shall mean, with respect to any product, the demonstration of
the reasonable technical and commercial efficacy and feasibility of such product for its intended
application.

     1.46 “Receiving Party” shall have the meaning set forth in Section 6.1.

     1.47 “Sample Preparation” shall mean the isolation, extraction and/or purification of
nucleic acid from tissue and bodily fluids obtained directly or indirectly from a human for
sequencing.

     1.48 “Sample Preparation [...***...]” shall mean, individually and collectively, the major
[...***...] of Sample Preparation System instruments.

     1.49 “Sample Preparation Systems” shall mean the reagents, methods, instruments and
associated consumables that are used for Sample Preparation, including those that are used for
Front End Sample Preparation.

     1.50 “Steering Committee” shall mean the committee comprising representatives of
Gen-Probe and PacBio as described in Section 3.1 below.

     1.51 “Stock Purchase Agreement” shall have the meaning set forth in the recitals.

     1.52 “Term” shall mean the period set forth in Section 8.1.

     1.53 “Third Generation Sequencing Systems” shall mean the reagents, methods,
instruments and associated consumables (including chips) that are used for single molecule
sequencing of nucleic acid, as developed by or on behalf of PacBio including without limitation
Single Molecule Real Time (SMRTTM) sequencing, the current PacBio RS system and the contemplated
PacBio [...***...] “V2” SMRT DNA sequencing platforms. Gen-Probe acknowledges that, as of the
Effective Date, PacBio’s Third Generation Sequencing Systems are [...***...].

     1.54 “Third Party” shall mean any Person other than Gen-Probe and PacBio and their
respective Affiliates.

     1.55 “V2 [...***...]” shall mean the primary [...***...] contained, or intended to be
contained, in the V2 System.

     1.56 “V2 Proof of Concept” shall have the meaning set forth on Exhibit C

     1.57 “V2 [...***...]” shall mean, individually and collectively, the V2 [...***...] and other
major sequencing [...***...] contained, or intended to be contained, in the V2 System.

***Confidential Treatment Requested

6

 

     1.58 “V2 System” shall mean the reagents, methods and instruments that are used for single
molecule sequencing of nucleic acids, as developed by or on behalf of PacBio, in the contemplated
“V2” SMRT DNA sequencing platform.

ARTICLE 2

PRODUCT DEVELOPMENT

     2.1 Development Plans.

          2.1.1 The initial program for the development of the Products is set forth in Exhibit
A (the “Initial Development Plan”).

          2.1.2 It is anticipated that progress made under the Initial Development Plan may necessitate
changes to the Initial Development Plan or, for any Products identified as warranting further
development activities, the adoption of additional development plans (the “Product Development
Plans,” and, together with the Initial Development Plan, the “Development Plans”).
Product Development Plans may be adopted and the Development Plans may be amended from time to
time by the Steering Committee in accordance with the provisions of Article 3. Such actions must
be in writing to be effective hereunder. The Development Plans may include, without limitation:
work schedules of activities that specify the development phases; time schedules for completion of
such phases; deliverables; key assumptions; itemized budgets by development phase, including agreed
costs; test methods; the timing of reimbursement payments, if any, tied to the completion of
milestones; scale-up activities; product specifications; the final activity that completes the
Development Plans; and the respective responsibilities of the parties.

          2.1.3 Each party shall designate a contact, which may be a member of the Steering Committee,
at their respective offices to receive and transmit communications concerning the Development
Plans.

          2.1.4 Gen-Probe and PacBio shall conduct their respective development obligations under the
Development Plans diligently and in accordance with the Development Plans and in compliance with
applicable laws, regulations and standards for good development practices. Gen-Probe and PacBio
each shall allocate sufficient personnel, equipment, facilities and other resources to the
Development Plans to carry out their respective obligations and use Commercially Reasonable Efforts
to accomplish the objectives thereof.

          2.1.5 Unless the Steering Committee determines otherwise, each party shall bear its own
expenses incurred in performing its obligations under this Agreement.

     2.2 Preferred Access Products.

          2.2.1 PacBio shall provide to Gen-Probe access to prototype versions of PacBio’s contemplated
Third Generation Sequencing System product families, through one or more collaborative research
projects to be performed using such prototype systems. Such collaborative research projects shall
be of nature and scope, and on such terms and conditions, as are mutually agreed by the parties;
provided that [...***...]

***Confidential Treatment Requested

7

 

[...***...].

          2.2.2 If, during the Term, PacBio initiates a beta testing program for any Third Generation
Sequencing System (whether stand-alone or incorporated into a Product), Gen-Probe shall be
permitted to serve as a beta test site for such system, subject to the then-current terms and
conditions for such beta test sites that have been established by PacBio for such Third Generation
Sequencing System, consistently applied, and subject to Gen-Probe’s continued fulfillment of its
obligations as a beta test site in accordance with such terms and conditions.

          2.2.3 During the Term and thereafter, Gen-Probe shall be entitled to purchase from PacBio, on
terms (including warranty terms) that are commercially reasonable for
both parties [...***...], any
Third Generation Sequencing System (whether stand-alone or incorporated into a Product) then
Commercially Available from PacBio to its customers generally; provided that such
entitlement shall survive a Change of Control of PacBio to the extent any such Third Generation
Sequencing System was, immediately prior to such Change in Control: (i) Commercially Available from
PacBio to its customers generally or (ii) (a) in active development by PacBio following a
successful Proof of Concept and (b) then intended by PacBio to be Commercially Available to its
customers generally in the future (provided, however, that PacBio shall not be
obligated to provide Gen-Probe such access earlier than when such Third Generation Sequencing
System is Commercially Available to PacBio’s customers generally).

          2.2.4 During the Term and thereafter, PacBio shall be entitled to purchase from Gen-Probe, on
terms (including warranty terms) that are commercially reasonable for
both parties [...***...], any
Sample Preparation System (whether stand-alone or incorporated into a Product) then Commercially
Available from Gen-Probe to its customers generally; provided that such entitlement shall
survive a Change of Control of Gen-Probe to the extent any such Sample Preparation System was,
immediately prior to such Change in Control: (i) Commercially Available from Gen-Probe to its
customers generally or (ii) (a) in active development by Gen-Probe following a successful Proof of
Concept and (b) then intended by Gen-Probe to be Commercially Available to its customers generally
in the future (provided, however, that Gen-Probe shall not be obligated to provide
PacBio such access earlier than when such Sample Preparation System is Commercially Available to
Gen-Probe’s customers generally).

          2.2.5 In addition to, and not in derogation of, Section 2.2.3, during the Term and thereafter,
Gen-Probe shall be entitled to purchase from PacBio, on terms (including warranty terms) that are
commercially reasonable for both parties [...***... ], any V2 [...***...] (whether stand-alone or embodied in
a system) and any Essential Ancillaries therefor, in each case, then Commercially Available from
PacBio; provided that such entitlement to purchase shall survive a Change of Control of
PacBio (i) with respect to the V2 [...***...] (and any Essential Ancillaries therefor), following a
successful V2 Proof of Concept and (ii) with respect to any other V2 [...***...] (and any Essential
Ancillaries therefor), to the extent any such V2 [...***...] was, immediately prior to such Change in
Control: (a) part of a V2 System

***Confidential Treatment Requested

8

 

Commercially Available from PacBio or (b) part of a V2 System in active development by PacBio in
its Collaboration with Gen-Probe hereunder following a successful Proof of Concept of such V2
[...***...] or V2 System; provided, further that any purchase pursuant to this Section
2.2.5 shall be for the sole purpose of Gen-Probe incorporating such V2 [...***...] into a Product
(regardless of whether such Product was developed under the Collaboration) to be sold in the Field,
and in no circumstances for the stand-alone resale of such V2 [...***...]. Upon written request in
accordance with Section 10.2 by PacBio to Gen-Probe after expiration or termination of this
Agreement or any such Change in Control, Gen-Probe shall, within ninety (90) days of receipt of
such request, provide to PacBio a good faith, commercially reasonable estimate of the likely
quantities and delivery dates for any V2 [...***...] (and any Essential Ancillaries therefor) which
Gen-Probe contemplates purchasing pursuant to this Section 2.2.5 over the course of the following
[...***...] calendar quarters. Gen-Probe shall continue to provide a rolling [...***...] calendar quarter
estimate, on a quarterly basis, so long as Gen-Probe desires to purchase any V2 [...***...] (and any
Essential Ancillaries therefor) pursuant to this Section 2.2.5.

          2.2.6 In addition to, and not in derogation of, Section 2.2.4, during the Term and thereafter,
PacBio shall be entitled to purchase from Gen-Probe, on terms (including warranty terms) that are
commercially reasonable for both parties [...***...], any Sample Preparation [...***...] (whether
stand-alone or embodied in a system) that is intended to be a part of any Product contemplated by
the Collaboration and any Essential Ancillaries therefor, in each case, then Commercially Available
from Gen-Probe; provided that such entitlement to purchase shall survive a Change of
Control of Gen-Probe with respect to any such Sample Preparation [...***...] (and any Essential
Ancillaries therefor), to the extent any such Sample Preparation [...***...] was, immediately prior to
such Change in Control, an intended part of a Product in active development by Gen-Probe following
a successful Proof of Concept of such Sample Preparation [...***...] or Product; provided,
further that any purchase pursuant to this Section 2.2.6 shall be for the sole purpose of
PacBio incorporating a Sample Preparation [...***...] into a Product (regardless of whether such
Product was developed under the Collaboration) to be sold in the Field, and in no circumstances for
the stand-alone resale of such Sample Preparation [...***...]. Upon written request in accordance with
Section 10.2 by Gen-Probe to PacBio after expiration or termination of this Agreement or any such
Change in Control, PacBio shall, within ninety (90) days of receipt of such request, provide to
Gen-Probe a good faith, commercially reasonable estimate of the likely quantities and delivery
dates for any Sample Preparation [...***...] (and any Essential Ancillaries therefor) which PacBio
contemplates purchasing pursuant to this Section 2.2.6 over the course of the following [...***...]
calendar quarters. PacBio shall continue to provide a rolling [...***...] calendar quarter estimate,
on a quarterly basis, so long as PacBio desires to purchase any Sample Preparation [...***...] (and any
Essential Ancillaries therefor) pursuant to this Section 2.2.6.

          2.2.7 The rights and obligations of the parties under this Section 2.2 shall apply equally to
the Affiliates of the parties and the provisions of this Section 2.2 shall be interpreted mutatis
mutandis with respect to the Affiliates of the parties, it being understood that each party may
elect to perform any or all of its obligations under this Section 2.2 exclusively through one or
more of its Affiliates (e.g., sale of products outside the U.S. via a non-U.S. Affiliate). Each
party shall cause its

***Confidential Treatment Requested

9

 

Affiliates, to the extent applicable, to comply with the provisions of this Section 2.2 as if they
were party to this Agreement.

     2.3 Access to Information.

          2.3.1 Gen-Probe shall provide PacBio access to relevant Diagnostics market research data that
Gen-Probe has generated, or will generate during the Term, including, without limitation, the
[...***...].

          2.3.2 PacBio shall provide Gen-Probe access to relevant Diagnostics market research data that
PacBio has generated, or will generate during the Term.

          2.3.3 Diagnostics market research data provided by one party to another under this Section 2.3
shall be considered Confidential Information pursuant to Article 6 of this Agreement. Without
limiting the foregoing, neither party shall reference or disclose Third Party study data
(including, without limitation, the [...***...]) without the prior written consent of such Third Party.

     2.4 Limited License Grants for Development Plans.

          2.4.1 License Grant by Gen-Probe. Gen-Probe hereby grants to PacBio a limited,
royalty-free, non-exclusive license, for the duration of the Term, to all of the Gen-Probe
Intellectual Property Rights reasonably required for PacBio to perform its obligations under the
Development Plans (the “Licensed GP IP”) and solely for such purposes. PacBio shall not
have the right to grant sublicenses under such license, without the express prior written consent
of Gen-Probe.

          2.4.2 License Grant by PacBio. PacBio hereby grants to Gen-Probe a limited,
royalty-free, non-exclusive license, for the duration of the Term, to all of the PacBio
Intellectual Property Rights reasonably required for Gen-Probe to perform its obligations under the
Development Plans (the “Licensed PacBio IP”) and solely for such purposes. Gen-Probe shall
not have the right to grant sublicenses under such license, without the express prior written
consent of PacBio.

     2.5 Subsequent Agreements. During the Term, the parties shall negotiate in good faith
one or more definitive agreements that shall set forth the economic and other terms and obligations
of the parties in furtherance of the continued development, commercialization and regulatory
clearance of the Products (the “Preferred Partnership Agreements”). Such Preferred
Partnership Agreements shall take into account the technological, commercial, regulatory and
reimbursement findings developed by the parties pursuant to this Agreement. Except as otherwise
provided in this Agreement, no party or its Affiliate shall take any steps, during the Term, to
commercialize in the Field any Product developed under the Collaboration or pursue any regulatory
clearances in the Field in respect of such Product prior to the execution of a Preferred
Partnership Agreement in respect of such Product.

***Confidential Treatment Requested

10

 

     2.6 Acknowledgements. Notwithstanding the parties’ intentions and obligations,
Gen-Probe and PacBio each: (i) expressly disclaims any representation or warranty that any
development activities taken pursuant to this Agreement will be successfully completed and (ii)
expressly acknowledges the possibility that any or all development or commercialization activities
may be unsuccessful despite the use of Commercially Reasonable Efforts. Both parties shall plan
accordingly.

ARTICLE 3

GOVERNANCE

     3.1 Steering Committee.

          3.1.1 The development of Products under the Development Plans shall be coordinated and
supervised by the Steering Committee, provided that a Development Plan, and any
modification of a Development Plan, shall not be considered to have been approved unless the budget
for a Development Plan or a modified Development Plan shall have been approved in writing by the
Chief Financial Officer of each party. The Steering Committee’s duties shall include
(i) determining the priorities of the Collaboration with respect to research activities, which
Products to develop and other development matters, (ii) maintaining the Development Plans,
including schedules of work and deliverable commitments by each party, (iii) maintaining an
accounting of the expenses borne by each party, (iv) facilitating open communication between the
parties on matters relating to the development findings and commercialization of Products in the
Field, and (v) engaging experts as necessary to identify the market, regulatory and reimbursement
requirements for integrating Sample Preparation Systems with Third Generation Sequencing Systems.
The Steering Committee shall have the power and authority to appoint joint project teams to oversee
and administer activities under this Agreement and shall set the roles and responsibilities for any
such project teams.

          3.1.2 The Steering Committee shall be comprised of three (3) named representatives of
Gen-Probe and three (3) named representatives of PacBio. PacBio and Gen-Probe shall each appoint
its respective representatives to the Steering Committee and each party may, from time to time and
in its sole discretion, substitute one or more of its representatives by giving notice to the other
party of such change. The initial members of the Steering Committee are set forth on Exhibit
B. Each party shall bear its own costs for its representatives’ participation on the Steering
Committee.

     3.2 Meetings. The Steering Committee shall convene not less than once each calendar
quarter during the Term. All meetings shall be set at times and places convenient to the members
of the Steering Committee as determined by the chair of the Steering Committee. Each party shall
bear its own travel costs in connection with travel to any meetings of the Steering Committee.

     3.3 Committee Actions. A party’s representatives on the Steering Committee shall
collectively have one vote as to all matters. All Steering Committee actions may only be taken by
unanimous vote of the parties. Any approval, determination or other action agreed to by both
parties’ representatives shall be the approval, determination or other action of the Steering
Committee. Except as may be otherwise specifically set forth in this Agreement, any matters as to
which the Steering Committee cannot reach a unanimous vote shall be presented to the respective
executives of the parties for consideration, in accordance with Article 9.

11

 

     3.4 Reports. Within thirty (30) days following each Steering Committee meeting, the
chairperson shall prepare and provide to each party a reasonably detailed written summary report
that shall describe any approval, determination or other action by the Steering Committee.

     3.5 Committee Procedures. Meetings of the Steering Committee shall be coordinated and
chaired by a representative of one of the parties. The position of chair shall rotate between the
parties each nine (9) months. PacBio shall have the right to appoint a representative to serve as
the chair of the Steering Committee for the first nine (9) months of the Term.

     3.6 Steering Committee Action Prior to End of Development Plans.

          3.6.1 In the event that either party reasonably concludes prior to the end of a Development
Plan that (i) the development schedule or development budget for a Product will materially exceed
the schedule or budget set forth in such Development Plan, (ii) development will not be able to be
conducted or be successfully concluded materially consistently with such Development Plan, or (iii)
based on anticipated market demand or for any other reason that the commercialization of such
Product in the Field would not likely be successful, such party shall promptly notify the Steering
Committee, which shall discuss all relevant circumstances and considerations and determine whether
any changes are needed to such Development Plan and, if so, make a decision on whether the
development work should continue with respect to such Product and whether to modify or terminate
such Development Plan.

          3.6.2 In the event a Development Plan is terminated under this Section 3.6, the termination
notice shall be effective on the date it is received. Such termination shall not in any way
relieve either party of obligations already incurred under the Development Plans prior to
termination, including obligations, if any, to reimburse the other party for any expense determined
to be reimbursable by the Steering Committee.

     3.7 Reports and Records. Once each calendar quarter prior to the Steering Committee
meeting, each party shall prepare a written summary report describing the work performed to date by
such party under all active Development Plans and provide such report to the other party. If
agreed by the parties, the foregoing reports may be oral reports given at the Steering Committee
meeting. Each party shall maintain complete and accurate records that fully and properly reflect
all work done and results achieved by it in the performance of the Development Plans (including all
data in the form required under all applicable laws and regulations).

     3.8 Inspection of Records. To the extent reasonably required for the performance of a
Development Plan, Gen-Probe and PacBio each shall have the right, during normal business hours and
upon reasonable notice, to inspect and copy records of the other party created in the course of
performing such Development Plan, to the extent such records are directly related to, and within
the scope of, the Collaboration. The parties shall develop reasonable procedures for requesting
and delivering copies of such records to each other. Each party shall maintain such records and
the information of the other party contained therein as Confidential Information hereunder.

12

 

     3.9 Subcontracts. Upon approval of the Steering Committee, which shall not be
unreasonably withheld by either party, each party may subcontract portions of any Development Plan
hereunder in the normal course of its business; provided, however, that unless the
other party gives its prior written consent, subcontracting with a Third Party shall not involve
the transfer or license (including any sublicense) of the other party’s intellectual property
rights and/or Confidential Information. If the other party consents to a subcontractor’s access to
Confidential Information of the other party, the subcontractor shall be required to enter into an
agreement including confidentiality terms that are at least as restrictive as the confidentiality
terms of Article 6 herein along with provisions for the assignment of inventions or intellectual
property rights arising from the subcontracted work. The subcontracting party shall supervise the
work of any subcontractor to ensure, in part, that the subcontractor’s work is in compliance in all
material respects with all requirements of the Development Plans and all applicable laws and
regulations. For purposes of this Section 3.9, subcontractors requiring approval of the Steering
Committee shall not include subcontractors that provide services on-site of either party in the
ordinary course of such party’s business; provided, however, that such excluded
subcontractors shall otherwise be subject to the requirements of this Section 3.9 to the extent
they work on any portion of any Development Plan or have access to the Confidential Information of
the other party.

     3.10 Withdrawal. Notwithstanding anything to the contrary in this Agreement, either
party may, upon thirty (30) days written notice to the other party, withdraw from participation in
the Steering Committee, in which case, the Steering Committee shall be dissolved and the parties
shall administer the Agreement without such committee, and shall make such amendments to the
Agreement as may be necessary or advisable in connection therewith. All decisions in this
Agreement that prior to such notice required the agreement of the Steering Committee, shall
following such notice be subject to the mutual agreement of the parties.

ARTICLE 4

EXCLUSIVITY

     4.1 Exclusivity. During the Term, neither party, and neither party’s Affiliates,
shall (i) jointly develop Products in the Field with any Third Party or (ii) directly or indirectly
grant to a Third Party an express license or an express immunity from suit with respect to any
technology used or useful in the Collaboration that would permit such Third Party to develop
Products in the Field using such technology either on its own, jointly with such party or with any
other Third Party; provided that a party shall not be precluded from joint development with
or out-licensing to a Third Party in respect of a particular Product if: (a) the parties, jointly
and in good faith, determine that one or both parties do not have sufficient capabilities required
for the development of a particular Product in the Field, (b) either party requests that the
Collaboration include the development of a particular Product in the Field and proposes fair terms
with respect to allocation of development costs, and the other party expressly disclaims
any interest in such development, or (c) such a license is granted in good faith in connection with
the [...***...]. Subject to the foregoing restrictions and the other party’s intellectual property
rights in a Product, each party shall be permitted to develop, promote, market and sell such
Product.

***Confidential Treatment Requested

13

 

ARTICLE 5

REPRESENTATIONS AND WARRANTIES

     5.1 Representations and Warranties. Each of Gen-Probe and PacBio hereby represents
and warrants as of the Effective Date (except as specifically otherwise indicated below) as
follows:

          5.1.1 Corporate Existence and Power. Such party (a) is a corporation duly organized,
validly existing and in good standing under the laws of the state in which it is incorporated; (b)
has the corporate power and authority and the legal right to own and operate its property and
assets, to lease the property and assets it operates under lease, and to carry on its business as
it is now being conducted; and (c) to its knowledge, is in compliance with all requirements of
applicable law, except to the extent that any noncompliance would not have a material adverse
effect on the properties, business, financial or other condition of such party and would not
materially adversely affect such party’s ability to perform its obligations under this Agreement.

          5.1.2 Authorization and Enforcement of Obligations. Such party (a) has the corporate
power and authority and the legal right to enter into this Agreement and to perform its obligations
hereunder and (b) has taken all necessary corporate action on its part to authorize the execution
and delivery of this Agreement and the performance of its obligations hereunder. This Agreement
has been duly executed and delivered on behalf of such party, and constitutes a legal, valid and
binding obligation, enforceable against such party in accordance with its terms.

          5.1.3 Consents. All necessary consents, approvals and authorizations of all
governmental authorities and other Persons required to be obtained by such party in connection with
the execution of this Agreement have been obtained on or before the Effective Date.

          5.1.4 No Conflict. To its knowledge, the execution and delivery of this Agreement and
the performance of such party’s obligations hereunder (a) do not conflict with or violate any
requirement of applicable laws or regulations, and (b) do not conflict with, or constitute a
default under, any material contractual obligation of such party.

          5.1.5 No Notice of Infringement. As of the Effective Date, except as otherwise
disclosed in writing to the other party, neither Gen-Probe nor PacBio has received any written
notice from a Third Party alleging that any technology of such party expected to be utilized in any
Product (each as and to the extent defined as of the Effective Date) to be developed pursuant to
this Agreement would infringe the issued patents of such Third Party.

     5.2 DISCLAIMER OF WARRANTIES. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A
REPRESENTATION MADE, OR WARRANTY GIVEN, BY GEN-PROBE OR PACBIO THAT ANY PATENT WILL ISSUE BASED
UPON ANY PENDING PATENT APPLICATION WITHIN THE GEN-PROBE PATENT RIGHTS OR THE PACBIO PATENT RIGHTS,
THAT ANY PATENT WITHIN THE GEN-PROBE PATENT RIGHTS OR THE PACBIO PATENT RIGHTS WHICH ISSUES WILL BE
VALID, OR THAT THE USE OF ANY LICENSE GRANTED HEREUNDER, OR THAT THE USE OF ANY GEN-PROBE PATENT
RIGHTS OR PACBIO PATENT RIGHTS WILL NOT INFRINGE THE PATENT OR OTHER INTELLECTUAL PROPERTY RIGHTS
OF ANY OTHER PERSON. FURTHERMORE, EACH OF GEN-PROBE

14

 

AND PACBIO DOES NOT MAKE, AND EXPRESSLY DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES, EXPRESS
OR IMPLIED, WITH RESPECT TO THE GEN-PROBE INTELLECTUAL PROPERTY RIGHTS AND THE PACBIO INTELLECTUAL
PROPERTY RIGHTS, RESPECTIVELY, OR TO THE PRODUCTS, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT.

ARTICLE 6

CONFIDENTIALITY

     6.1 Confidential Information. For the period commencing on the Effective Date and
ending seven (7) years following the expiration or earlier termination hereof, a party and its
Affiliates and their respective directors, officers, employees and consultants (the “Receiving
Parties”) shall maintain in confidence the Confidential Information of the other party and its
Affiliates, and shall not disclose to Third Parties the Confidential Information of the other party
or its Affiliates (the “Disclosing Parties”) except to Affiliates of the Receiving Parties
and their respective directors, officers, employees and consultants involved in the performance of
obligations under this Agreement. To the extent that disclosure to any Third Party is authorized
by this Agreement, prior to disclosure, the Receiving Party shall obtain written agreement of such
Third Party to hold in confidence and not disclose, use or grant the use of the Confidential
Information of the other party except as expressly permitted under this Agreement. The parties
agree that the term of the non-disclosure and non-use obligations of a Third Party shall be
co-extensive with the confidentiality obligations of the parties hereunder. A Receiving Party
shall notify the applicable Disclosing Party promptly upon discovery of any unauthorized use or
disclosure of the Disclosing Party’s Confidential Information. Upon the expiration or earlier
termination of this Agreement, each Receiving Party shall return to the applicable Disclosing Party
all tangible items regarding the Confidential Information of the Disclosing Party and all copies
thereof; provided, however, that a Receiving Party shall have the right to retain
one (1) copy for its legal files for the sole purpose of determining its obligations hereunder.
Each party shall cause its Affiliates, to the extent applicable, to comply with the provisions of
this Section 6.1 as if they were party to this Agreement.

     6.2 Terms of this Agreement. For the period commencing on the Effective Date and
ending on the expiration or earlier termination hereof, without the prior express written consent
of the other party, which shall not be unreasonably withheld or delayed, neither party nor its
Affiliates shall (a) disclose any financial terms or conditions of this Agreement to any Third
Party, except as reasonably required in connection with such party’s activities hereunder and under
appropriate confidentiality restrictions; or (b) originate any initial disclosure to any Third
Party of the existence or terms of this Agreement; or (c) originate any initial publicity, news
release or any other public announcement (written or oral) relating to this Agreement or the
existence of an arrangement among the parties. Notwithstanding the foregoing, the parties shall be
allowed to issue mutually agreed upon individual or joint press releases disclosing the general
nature of the Collaboration. Either party shall thereafter be free to disclose any information
contained in the public disclosure approved pursuant to this Section 6.2 or which is made without
confidentiality restrictions pursuant to Section 6.3.

15

 

     6.3 Permitted Disclosures. The confidentiality obligations under this Article 6 shall not
apply to the extent that a party is required to disclose information by applicable law, regulation
or order of a governmental agency or a court of competent jurisdiction; provided that such
party shall provide written notice thereof to the other party and sufficient opportunity to contest
any such disclosure or to request confidential treatment thereof.

ARTICLE 7

DEVELOPED INTELLECTUAL PROPERTY; INTELLECTUAL PROPERTY RIGHTS;

 ENFORCEMENT

     7.1 Ownership of Inventions. Except as set forth in this Article 7, the entire
worldwide right, title and interest in all patentable discoveries, inventions and technology, made
or developed in the course of the Collaboration, and in any patents or patent applications therein,
(a) solely by employees of Gen-Probe or others acting on behalf of Gen-Probe (the “Gen-Probe
Inventions”) shall, as between Gen-Probe and PacBio, be owned solely by Gen-Probe, (b) solely
by employees of PacBio or others acting on behalf of PacBio (the “PacBio Inventions”)
shall, as between PacBio and Gen-Probe, be owned solely by PacBio, and (c) jointly by employees of
Gen-Probe or others acting on behalf of Gen-Probe and employees of PacBio or others acting on
behalf of PacBio (the “Joint Inventions”) shall, as between Gen-Probe and PacBio, be owned
jointly by Gen-Probe and PacBio. Any dispute as to which party owns any such patentable
discoveries, inventions, technology, patents or patent applications shall be resolved pursuant to
Article 9. Each party hereby assigns any such right, title and interest that it may have to the
other party to effect the foregoing allocation of ownership rights and, for such purpose, it shall
execute such documents, including assignment agreements and take such steps as reasonably requested
by the other party.

     7.2 Patent Applications and Payment of Related Expenses.

          7.2.1 PacBio shall be responsible for and shall control, at its sole discretion and expense,
the preparation, filing, prosecution, maintenance and enforcement of all PacBio Patent Rights that
are the subject of this Agreement. Gen-Probe shall be responsible for and shall control, at its
sole expense, the preparation, filing, prosecution, maintenance and enforcement of all Gen-Probe
Patent Rights that are the subject of this Agreement.

          7.2.2 The Steering Committee shall establish a strategy for, including the appointment of a
party to lead, the preparation, filing, prosecution and maintenance of patent applications and
patents for Joint Inventions. Unless otherwise agreed, the parties shall share equally in the
costs, fees and expenses associated with the preparation, filing and prosecution of any patent
application claiming a Joint Invention and for the maintenance of such Joint Inventions. In the
event Gen-Probe or PacBio fails or elects not to pay its share of any of the foregoing costs, fees
or expenses, it shall assign its entire interest in such Joint Inventions to the other party.
Unless otherwise agreed, patent applications claiming Joint Inventions shall be prepared and
prosecuted promptly by mutually acceptable outside counsel. In the preparation and prosecution of
patent applications claiming Joint Inventions, each party shall be solely responsible for
communicating its interests to the outside counsel, and no employee of any party shall in any way
act as the attorney, agent, or representative of any other party, or otherwise in any way be
responsible for representing or protecting the interests of any other party. All decisions of the
outside counsel shall be final and binding. To the extent not inconsistent with this Agreement,

16

 

neither party may assert any claims against the other party for any act or omission in the
preparation, filing, prosecution, issuance, maintenance, licensing, enforcement or defense of
patent applications or patents issuing therefrom claiming Joint Inventions.

          7.2.3 The parties shall cooperate with one another to the extent necessary in connection with
the filing of patent applications for their respective inventions and for Joint Inventions. Within
a reasonable period of time after a party files any patent application during or after the Term
claiming a Joint Invention conceived during and as a result of the performance of this Agreement,
the party filing such an application shall provide the other party with a copy of the application
and shall identify with reasonable specificity any Confidential Information of such other party
that may be included therein. The party receiving the copy of the application shall then have one
(1) month to review the application and notify the filing party as to whether any of the receiving
party’s Confidential Information is disclosed. If the patent application contains any such
Confidential Information or if the filing party shall be required to disclose any Confidential
Information pursuant to filing such application, then the filing party shall withdraw such
application (without retaining a residual right to claim priority) before any publication, unless
the filing party is given the permission of the other party, which permission shall only be
withheld if disclosure of such Confidential Information has a adverse impact upon the interests of
the party having the right to prevent the disclosure of such Confidential Information.

     7.3 Copyrights.

          7.3.1 Ownership. Except as set forth in this Article 7, the entire worldwide right,
title and interest in all copyrightable works created in the course of the Collaboration (a) solely
by employees of Gen-Probe or others acting n behalf of Gen-Probe shall be owned solely by
Gen-Probe, (b) solely by employees of PacBio or others acting on behalf of PacBio shall be owned
solely by PacBio, and (c) jointly by employees of Gen-Probe or others acting on behalf of Gen-Probe
and employees of PacBio or others acting on behalf of PacBio (the “Joint Copyrights”) shall
be owned jointly by Gen-Probe and PacBio.

          7.3.2 Copyright Protection. In order to protect against infringement of a party’s
copyrights or of Joint Copyrights, the parties shall cooperate to apply an appropriate copyright
mark to all materials identified by each of the parties as copyrightable materials that are created
in the course of the Collaboration. Each party shall cooperate with the other party, take such
actions and execute such documents, as reasonably requested by the other party and at the other
party’s expense, to assist the other party in the protection of the other party’s copyrights. Each
party hereby covenants to take no action or make no omission which would constitute an infringement
of the other party’s claim of copyright protection with respect to such items. Any dispute as to
which party owns a copyright shall be resolved pursuant to Article 9. Each party hereby assigns
any such right, title and interest that it may have to the other party to effect the foregoing
allocation of ownership rights and, for such purpose, it shall execute such documents, including
assignment agreements and take such steps as reasonably requested by the other party.

     7.4 Know-How. Except as set forth in this Article 7, the entire worldwide right,
title and interest in any know-how, trade secrets, information, expertise or data (including
formulae, procedures, protocols, techniques, data and results of experimentation and testing) not
otherwise addressed in Sections 7.1 or 7.3.1 and developed or created in the course of the
Collaboration (a) solely by

17

 

employees of Gen-Probe or others acting on behalf of Gen-Probe shall be owned solely by
Gen-Probe, (b) solely by employees of PacBio or others acting on behalf of PacBio shall be owned
solely by PacBio, and (c) jointly by employees of Gen-Probe or others acting on behalf of Gen-Probe
and employees of PacBio or others acting on behalf of PacBio (the “Joint Know-How”) shall
be owned jointly by Gen-Probe and PacBio. Any dispute as to which party owns any such know-how,
trade secrets, information, expertise or data (including formulae, procedures, protocols,
techniques, data and results of experimentation and testing) shall be resolved pursuant to Article
9. Each party hereby assigns any such right, title and interest that it may have to the other
party to effect the foregoing allocation of ownership rights and, for such purpose, it shall
execute such documents, including assignment rights and take such steps as reasonably requested by
the other party.

     7.5 Derivative Intellectual Property.

          7.5.1 Notwithstanding Sections 7.1, 7.3, 7.4 and 7.6, the entire worldwide right, title and
interest in any discoveries, inventions, technology, know-how, trade secrets, information,
expertise or data (including formulae, procedures, protocols, techniques, data, results of
experimentation and testing), and copyrightable works developed or created in the course of the
Collaboration that are based on, or constitute improvements, enhancements or modifications of, (a)
the Licensed GP IP (the “Gen-Probe Derivative IP”) shall be owned solely by Gen-Probe, and
(b) the Licensed PacBio IP (the “PacBio Derivative IP”) shall be owned solely by PacBio;
provided that any discoveries, inventions, technology, know-how, trade secrets,
information, expertise or data (including formulae, procedures, protocols, techniques, data,
results of experimentation and testing), and copyrightable works developed or created in the course
of the Collaboration that use, are based on or incorporate any of, or constitute improvements,
enhancements or modifications of both the Licensed GP IP and the Licensed PacBio IP shall be deemed
Joint Intellectual Property, and as applicable, Joint Inventions, Joint Copyrights, or Joint
Know-How.

          7.5.2 Each party shall assign any right, title and interest that it may have to the other
party to effect the allocation of ownership rights set forth in Section 7.5.1 and shall cooperate
with the other party, execute such documents, including assignment agreements, and take such steps,
as reasonably requested by the other party and at the other party’s expense, to assist the other
party in the protection of the other party’s rights pursuant to Section 7.5.1.

     7.6 Rights over Joint Intellectual Property. Each party shall own an equal undivided
interest in all Joint Inventions, Joint Copyrights and Joint Know-How (including Diagnostic market
requirements developed during the course of performing the Collaboration, to the extent not
otherwise included in the foregoing) (collectively, the “Joint Intellectual Property”) and
shall have the right, subject to the provisions of this Agreement, to use, pledge, license, assign
or otherwise transfer, its rights in any such Joint Intellectual Property hereunder without the
permission, consent of, or compensation or accounting to, the other party, except to the extent
that such use or application of Joint Intellectual Property would require a license from the other
party (e.g., under a claim other than that which claims the Joint Intellectual Property).

     7.7 No Other Technology Rights. Except as otherwise expressly provided in this
Agreement, under no circumstances shall a party, as a result of this Agreement, obtain any
ownership interest or other right in any discovery, invention or other technology, data or
information (or any patent, copyright, trademark, or other intellectual property rights therein) of
the other party, including

18

 

items transferred by the other party to such party at any time pursuant to this Agreement.
There are no implied licenses or rights granted by this Agreement and no implied licenses or
rights, and no licenses or rights by estoppel, shall be created by the parties’ course of
performance hereunder. Except as expressly provided in this Agreement, neither party shall be
under any obligation to grant to the other party any rights in any patent, copyright, trademark, or
other intellectual property.

     7.8 Third Party Technology. The Steering Committee shall discuss Third Party
intellectual property rights that may be necessary for the Products. Any such discussions shall,
to the extent advisable, take place with legal counsel present in order to preserve legal
privileges available to the parties. The Steering Committee shall consider the costs of acquiring
rights in such Third Party intellectual property rights in connection with such Products, allocate
the costs as appropriate, and agree upon methods for implementing such cost allocations. The
Steering Committee shall also consider which party shall take the lead in initiating contact with
and negotiating with the Third Party. The parties recognize that if the Steering Committee cannot
agree on such cost allocation, neither party shall be under any obligation to separately acquire
such rights for use pursuant to this Agreement.

     7.9 Enforcement. In the event that either party learns of any Third Party
infringement of the Joint Intellectual Property, such party shall promptly provide written notice
to the other party, including any evidence of infringement in the possession of the disclosing
party.

          7.9.1 Except as set forth in this Section 7.9.1, PacBio and Gen-Probe shall jointly defend and
enforce any rights in any Joint Intellectual Property so that the legal fees, costs and expenses of
both parties and any damage awards are shared equally, and with any damages payable to a Third
Party or any recoveries from a Third Party resulting from the enforcement or defense of such rights
being shared equally. To the extent necessary, the parties shall appoint a party to lead the
defense and enforcement of such rights. The parties shall cooperate fully with one another in
legal matters relating to Joint Intellectual Property, including, but not limited to, providing
testimony and executing documents. Both parties have the right, but not the obligation, to
participate in any action or proceeding with respect to Joint Intellectual Property by counsel of
its own choice. Absent further agreement of the parties, and subject to Section 7.9.2, each party
may elect not to participate in any enforcement action or proceeding and may elect not to pay its
shares of the legal fees, costs and expenses incurred in connection with such action or proceeding.
Neither party shall settle any enforcement action or proceeding without the other party’s prior
written consent if the proposed settlement will impact the other party’s rights under the Joint
Intellectual Property (e.g., by admitting invalidity). In any event, if both parties are
participating in an enforcement action or proceeding, then neither party shall settle such action
or proceeding without the other party’s prior written consent.

          7.9.2 Subject to 7.9.1, any recovery or other relief for infringement of Joint Intellectual
Property shall first be allocated to reimburse the reasonable and actual expenses incurred in the
enforcement process in a manner that results in equal net expenses to PacBio and to Gen-Probe. Any
remainder shall be shared equally by PacBio and Gen-Probe if they both participated (i.e., such
that the legal fees, costs and expenses of both parties and any damage awards are shared equally)
in the enforcement process. If only one party participated in the enforcement process, the
participating party shall be solely entitled to the relief obtained in the enforcement action or
proceeding.

19

 

     7.10 Third Party Infringement. In the event that any Third Party makes a written claim or
demand, or brings an action, suit or proceeding (collectively, an “Action”), against either
party, alleging infringement, unauthorized use or misappropriation of such Third Party’s patents,
copyrights, technology, other intellectual property rights or confidential information, and an
adverse result from such Action is reasonably likely to have a material impact on the development
of any Products in the Field in the good faith determination of such party, such party shall
promptly notify the other party in writing, and provide copies of all materials or papers received
by or served on such party from or by such Third Party. For the avoidance of doubt, the parties’
respective obligations to each other with respect to any Third Party Actions arising out of, in
connection with or relating to either party’s sale or use of any Product or Preferred Access
Product shall be as set forth in the Preferred Partnership Agreement for such Product or the
supply agreement for such Preferred Access Product, respectively.

          7.10.1 If an Action relates primarily to the Gen-Probe Intellectual Property Rights, Gen-Probe
shall be primarily responsible for responding to the Action, including controlling any litigation
and, unless otherwise agreed by the parties, paying the fees, costs and expenses relating thereto
or in settlement thereof.

          7.10.2 If an Action relates primarily to the PacBio Intellectual Property Rights, PacBio shall
be primarily responsible for responding to the Action, including controlling any litigation and,
unless otherwise agreed by the parties, paying any fees, costs and expenses relating thereto or in
settlement thereof.

          7.10.3 The principles of Section 7.9.1 shall apply with respect to any Action that reasonably
relates to any Joint Intellectual Property.

     7.11 Nothing herein shall require a party to acquire Third Party intellectual property, and
the parties acknowledge that a Third Party claim of infringement is subject to Section 7.8 as to
the prospective use of the Third Party technology. In the event that any Third Party intellectual
property rights are judicially determined to preclude the manufacture, use or sale of any Product
in the Field and the parties are unable to obtain prospective rights to such Third Party
intellectual property rights on commercially reasonable terms, either party shall have the right to
terminate development activities with respect to such Product. The termination of development
activities by either party under this Section 7.11 shall mean that the Product shall cease to be an
object of development efforts for all purposes under this Agreement and each party shall be
permitted to develop, promote, market and sell such Product, subject to the other party’s
intellectual property rights in such Product, notwithstanding any provision of this Agreement to
the contrary (including without regard to the exclusivity provisions of Article 4).

20

 

ARTICLE 8

TERM AND TERMINATION

     8.1 Expiration. Unless terminated earlier pursuant to Section 8.2 below, this
Agreement shall expire on the earlier of: (i) six (6) months after delivery by PacBio to Gen-Probe
of a summary report establishing successful V2 Proof of Concept and (ii) thirty (30) months after
the Effective Date, provided that in no event shall the Agreement expire prior to eighteen (18)
months after the Effective Date (the “Term”). Upon the further written agreement by the
parties effected prior to the expiration of the then-applicable Term, PacBio and Gen-Probe may
renew this Agreement and extend the original Term.

     8.2 Termination.

          8.2.1 Breach. Each party may terminate this Agreement after the material breach of
this Agreement by the other party, unless the breaching party has cured such breach within sixty
(60) days after notice thereof from the non-breaching party. Any dispute with respect to the right
of a party to terminate all or a portion of this Agreement shall be subject to resolution pursuant
to Article 9.

          8.2.2 Voluntary Bankruptcy. Each party may terminate this Agreement if the other
party shall (a) seek the liquidation, dissolution, or winding up of itself (other than a
liquidation of a solvent company for organizational purposes) or the readjustment of all or
substantially all of its debts, (b) apply for or consent to the appointment of, or the taking of
possession by, a receiver, custodian, trustee or liquidator of itself or of all or substantially
all of its assets, (c) make a general assignment for the benefit of its creditors, (d) commence a
voluntary case under the Bankruptcy Code, (e) file a petition seeking to take advantage of any
other law relating to bankruptcy, insolvency, reorganization, winding-up or readjustment of debts,
or (f) adopt any resolution of its Board of Directors or stockholders for the purpose of effecting
any of the foregoing.

          8.2.3 Involuntary Bankruptcy. Each party may terminate this Agreement if a proceeding
or case shall be commenced without the application or consent of the other party and such
proceeding or case shall continue undismissed, or an order, judgment or decree approving or
ordering any of the following shall be entered and continue unstayed in effect, for a period of
ninety (90) days from and after the date service of process is effected upon the other party,
seeking (a) its liquidation, reorganization, dissolution or winding up, or the readjustment of all
or substantially all of its debts, (b) the appointment of a trustee, receiver, custodian,
liquidator or the like of itself or of all or substantially all of its assets, or (c) similar
relief under any law relating to bankruptcy, insolvency, reorganization, winding up or readjustment
of debts.

          8.2.4 Acquisition by a Competitor. Each party may terminate this Agreement if the
other party undergoes a Change of Control whereby (a) the other party is acquired by, merged with
or reorganized or consolidated into a competitor of the terminating party (or an Affiliate of such
competitor), or (b) the terminating party’s competitor (or its Affiliate) becomes an Affiliate of
the other party. For purposes hereof, (a) PacBio’s “competitors” shall include [...***...], their
respective assigns and successors in interest, and any other entity that competes with PacBio in
the DNA sequencing field as of the date of the Change of Control, and (b) Gen-Probe’s “competitors”
shall include [...***...]

***Confidential Treatment Requested

21

 

[...***...], their respective assigns and successors in interest, and any other entity that
competes with Gen-Probe in the molecular Diagnostics field as of the date of the Change of Control.

     8.3 Effect of Expiration and Termination. Except to the extent otherwise provided in
this Agreement, upon expiration or termination of this Agreement, all rights and licenses granted
hereunder shall terminate. Expiration or termination of this Agreement shall not relieve the
parties of any obligation accruing prior to such expiration or termination. The provisions of this
Section 8.3, the provisions of Sections 2.2 (excluding Sections 2.2.1 and 2.2.2), 5.2 and 8.2.1
and Articles 6, 7, 9 and 10 shall survive the expiration or termination of this Agreement,
provided, however, that in the case of a termination prior to expiration of this
Agreement, Sections 2.2.3, 2.2.4, 2.2.5 and 2.2.6 shall survive such termination solely in respect
of the right of the party entitled to declare a termination to purchase Preferred Access Products
of the other party.

ARTICLE 9

DISPUTE RESOLUTION AND GOVERNING LAW

     9.1 Order. Disputes arising between the parties relating to the making or performance
of this Agreement (including ownership of intellectual property rights, breach of confidentiality,
inventorship, etc.) shall be resolved in the following order: (i) by good faith negotiation
between executives of PacBio and Gen-Probe who have authority to fully and finally resolve the
dispute; (ii) if necessary, by non-binding mediation at a location acceptable to the parties using
a neutral mediator having experience with the industry (with the costs therefore shared equally);
or (iii) as a last resort only, by arbitration of inventorship disputes as provided in Section 9.2,
or by arbitration of any other disputes in accordance with Section 9.3. All negotiations pursuant
to this clause shall be treated as Confidential Information in accordance with the provisions of
Article 6 of this Agreement, and shall also be treated as compromise and settlement negotiations
for purposes of Rule 408 of the Federal Rules of Evidence and comparable state rules of evidence.

     9.2 Inventorship Disputes. If the parties are unable to resolve any dispute regarding
inventorship by negotiation or mediation under Section 9.1, they shall submit such dispute to
binding arbitration under the C.P.R. Institute for Dispute Resolution Rules for Non-Administered
Arbitration of Patent and Trade Secret Disputes. The arbitrator shall be an independent patent
attorney residing in the United States and registered to practice before the United States Patent
and Trademark Office. The parties shall request that the arbitrator resolve the inventorship
dispute in accordance with the laws of the United States within three (3) months of his or her
appointment. The parties shall supply to the arbitrator documentary evidence of inventorship
together with a written statement of their position not to exceed twenty (20) pages in length
within twenty (20) days of the appointment of the arbitrator. Unless the parties agree to rely on
affidavits, the arbitrator shall set a hearing at which each party shall have up to eight (8) hours
to present witnesses and to cross examine the witnesses of the other party. If there is a hearing,
each party shall provide a statement summarizing the testimony of each witness it may have testify
to the other party and the arbitrator at least fifteen (15) days in advance of the hearing. The
parties shall request that the arbitrator’s award be in writing not to exceed twenty (20) pages in
length and shall include reasoning in support of the award. The resolution of the arbitrator shall
be final and binding on the parties, without right of appeal.

***Confidential Treatment Requested

22

 

     9.3 Arbitration Procedure. Except as provided for in Section 9.2, any controversy or
claim relating to, arising out of, or in any way connected to any provision of this Agreement shall
be finally resolved by final and binding arbitration in accordance with this Section by a single
arbitrator who is a former state or federal judge, to be conducted in San Francisco, California if
initiated by Gen-Probe, or in San Diego, California if initiated by PacBio, or in such other
location as mutually agreed by the parties. Unless the parties agree otherwise, the arbitration
shall be conducted by the Judicial Arbitration and Mediation Services, Inc. (“JAMS”), or by
any similar arbitration provider who can provide a former judge to conduct such arbitration if JAMS
is no longer in existence. JAMS may order a change of venue upon a showing of good cause by
respondent. The decision of the arbitrator shall be final, nonappealable and binding upon the
parties, and it may be entered in any court of competent jurisdiction. The arbitrator shall be
bound by all rules relating to the admissibility of evidence, including without limitation, all
relevant privileges and the attorney work product doctrine. Discovery shall be permitted in
accordance with the rules and procedures of the forum state unless otherwise agreed to by the
parties or ordered by the arbitrator on the basis of strict necessity adequately demonstrated by
the party requesting an extension of time. The arbitrator shall have the power to grant equitable
relief where applicable under the law. The arbitrator shall issue a written opinion setting forth
his or her decision and the reasons therefor within thirty (30) days after the arbitration
proceeding is concluded. The obligation of the parties to submit any dispute arising under or
related to this Agreement to arbitration as provided in this Article 9 shall survive the expiration
or earlier termination of this Agreement.

     9.4 Confidentiality. The existence of and any facts or documents related to any
proceedings under Sections 9.1, 9.2, and 9.3 shall be treated as Confidential Information in
accordance with the provisions of Article 6 of this Agreement. Any mediator or arbitrator shall be
bound by an agreement containing confidentiality provisions at least as restrictive as those
contained in Article 6 of this Agreement.

     9.5 Equitable Considerations. Nothing in this Article 9 shall preclude any party from
taking whatever actions are necessary to prevent immediate, irreparable harm to its interests.

     9.6 Damages. The parties each agree to waive any right to receive punitive, indirect,
incidental, special or consequential damages (including, but not limited to, loss of profits,
revenue, or business) relating in any way to this Agreement; provided, however,
that the foregoing waiver shall not apply to any breach of a party’s obligations of confidentiality
under Article 6.

     9.7 Applicable Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of California, without regard to the conflicts of law principles
thereof. The parties agree that the State of California has a substantial relationship to this
transaction and each party agrees that the courts of California shall have exclusive jurisdiction
over them and agree to submit to the jurisdiction of such courts. Accordingly, any and all
litigation, including without limitation litigation relating to this Agreement, shall be brought
exclusively in the State of California in the state or federal court having subject matter
jurisdiction.

23

 

ARTICLE 10

MISCELLANEOUS

     10.1 Limitation of Liability.

          10.1.1 LIMITATION OF LIABILITY. UNDER NO CIRCUMSTANCES EXCEPT FOR A BREACH OF A
PARTY’S OBLIGATIONS OF CONFIDENTIALITY UNDER ARTICLE 6 SHALL A PARTY BE LIABLE FOR PUNITIVE,
INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT NOT LIMITED TO, LOSS OF
PROFITS, REVENUE, OR BUSINESS) IN ANY WAY RELATED TO THIS AGREEMENT, OR THE TERMINATION OF THIS
AGREEMENT, OR ARISING OUT OF OR ALLEGED TO HAVE ARISEN OUT OF (i) BREACH OF THIS AGREEMENT, (ii)
THE FAILURE BY EITHER PARTY TO DEVELOP ANY PRODUCTS OR PROCESSES IN ACCORDANCE WITH ANY DEVELOPMENT
PLAN, (iii) THE FAILURE BY EITHER PARTY TO DEVOTE THE RESOURCES SPECIFIED IN ANY DEVELOPMENT PLAN,
(iv) THE FAILURE BY EITHER PARTY TO COMPLY WITH THE TERMS OF A DEVELOPMENT PLAN, OR (v) ANY EVENT
RELATED TO THE CONDUCT OF ANY DEVELOPMENT PLAN. This limitation applies regardless of whether such
damages are sought based on breach of contract, negligence, or any other legal theory.

     10.2 Notices. Any consent, notice or report required or permitted to be given or made
under this Agreement by one party to the other shall be in writing, addressed to such other party
at its address indicated below, or to such other address as the addressee shall have last furnished
in writing to the addressor, and shall be effective: (i) if sent by registered or certified mail in
the United States return receipt requested, upon receipt; (ii) if sent by nationally recognized
overnight air courier (such as DHL or Federal Express), two (2) business days after mailing; (iii)
if sent by facsimile transmission, with a copy mailed on the same day in the manner provided in
clauses (i) or (ii) of this Section 10.2, when transmitted and receipt is confirmed by telephone or
e-mail; and (iv) if otherwise actually personally delivered, when delivered.

			
	     If to Gen-Probe:	 	Gen-Probe Incorporated

10210 Genetic Center Drive

San Diego, California 92121

Attention: President and CEO

With a copy to:

Gen-Probe Incorporated

10210 Genetic Center Drive

San Diego, California 92121

Attention: General Counsel

and

24

 

			
	             	 	Debevoise & Plimpton LLP

919 Third Avenue

New York, NY 10022

Attention: Andrew L. Bab

			
	      If to PacBio:	 	Pacific Biosciences of California, Inc.

1505 Adams Drive

Menlo Park, CA 94025

Attention: CEO 

With a copy to:

Pacific Biosciences of California, Inc.

1505 Adams Drive

Menlo Park, CA 94025

Attention: General Counsel

     10.3 Force Majeure. In the event that a party is prevented or delayed from fulfilling
or performing any of its obligations under this Agreement (other than an obligation to pay money)
due to the occurrence of causes beyond the reasonable control of such party, including fires,
floods, embargoes, wars, acts of war (whether war is declared or not), insurrections, riots, civil
commotions, strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays
in acting by any governmental authority or the other party, then such party’s performance shall be
excused, and the time for performance shall be extended, for the period of inability or delay due
to such occurrence; provided, however, that such party shall have used its
Commercially Reasonable Efforts to avoid such inability or delay, and such party shall have given
prompt written notice to the other party of such occurrence.

     10.4 Assignment.

          10.4.1 This Agreement may not be directly or indirectly assigned or otherwise transferred,
nor, except as expressly provided hereunder, may any right or obligations hereunder be assigned or
transferred by a party (whether voluntarily, by operation of law or otherwise) without the consent
of the other party which shall not be unreasonably withheld: provided, however,
that, except as otherwise provided in Section 10.5 below, either party may, without such consent,
assign or transfer this Agreement and its rights and obligations hereunder in connection with the
transfer or sale of all or substantially all of its assets related to this Agreement or in the
event of its merger, consolidation, other change in control or similar transaction. Any permitted
assignee or transferee shall assume all obligations of its assignor or transferor under this
Agreement. Any purported assignment or transfer in violation of this Section shall be void.

25

 

          10.4.2 Assignment by a party of its rights and obligations under this Agreement shall not relieve
that party of its obligations under Articles 6 and 7 hereof.

     10.5 Change in Control. Each of the parties shall notify the other party as promptly
as possible after any effected Change of Control. The party receiving the notice of Change of
Control may require the party subject to the Change of Control to provide adequate assurance of
performance of the Agreement.

     10.6 Severability. Each party hereby acknowledges that it does not intend to violate
any public policy, statutory or common laws, rules, regulations, treaty or decision of any
government agency or executive body thereof of any country or community or association of
countries. Should one or more provisions of this Agreement be or become invalid, the parties shall
substitute, by mutual consent, valid provisions for such invalid provisions, which valid provisions
in their economic effect are sufficiently similar to the invalid provisions that it can be
reasonably assumed that the parties would have entered into this Agreement with such provisions.
In case such provisions cannot be agreed upon, the invalidity of one or several provisions of this
Agreement shall not affect the validity of this Agreement as a whole, unless the invalid provisions
are of such essential importance to this Agreement that it is to be reasonably assumed that the
parties would not have entered into this Agreement without the invalid provisions.

     10.7 Entire Agreement. This Agreement contains the entire understanding of the
parties with respect to the subject matter hereof from and after the Effective Date. All express
or implied agreements and understandings, either oral or written heretofore made which are directly
related to the subject matter of this Agreement are superceded by this Agreement, except to the
extent of rights and obligations pursuant to the Confidentiality Agreement which had accrued as of
the Effective Date. The parties acknowledge that they are also party to the Stock Purchase
Agreement and that the provisions of that agreement, or differences between that agreement and this
Agreement, shall not influence the interpretation of this Agreement. This Agreement may be
amended, or any term hereof modified, only by a written instrument duly executed by PacBio and
Gen-Probe.

     10.8 Independent Contractors. It is expressly agreed that Gen-Probe and PacBio shall
be independent contractors and that the relationship between the parties shall not constitute a
partnership, joint venture or agency. Neither Gen-Probe nor PacBio shall have the authority to
make any statements, representations or commitments of any kind, or to take any action, which shall
be binding on the other, without the prior consent of the party to do so.

     10.9 No Solicitation. Each party agrees that for a period beginning on the Effective
Date and ending on the close of business on the date two years following the termination or
expiration of this Agreement, neither party nor any of its Affiliates shall solicit to employ any
officer of the other party or any employee of the other party that is involved in the performance
of this Agreement (which shall include research and development employees and members of the
Steering Committee), without obtaining the prior written consent of the other party (it being
understood that any newspaper or public solicitation not directed specifically to such Person shall
not be deemed to be a solicitation for purposes of this provision); provided that this
Section 10.9 shall not prohibit a party or such party’s Affiliates from discussing employment
opportunities with, or hiring, any officer or employee of the other party involved in the
performance of this Agreement who initiates such discussions with such party or such party’s
Affiliates.

26

 

     10.10 Waiver. The waiver by a party of any right hereunder or the failure to perform or of
a breach by the other party shall not be deemed a waiver of any other right hereunder or of any
other breach or failure by said other party whether of a similar nature or otherwise.

     10.11 Drafting Party; Interpretation. The provisions of this Agreement, and the
documents and instruments referred to in the Agreement, have been prepared, examined, negotiated
and revised by each party and their respective lawyers, and no implication shall be drawn and no
provision shall be construed against any party by virtue of the purported identity of the drafter
of this Agreement, or any portion of this Agreement. The headings contained in this Agreement are
for convenience of reference only, shall not be deemed a part of this Agreement and shall not be
referred to in connection with the construction or interpretation of this Agreement. As used in
this Agreement, the words “include” and “including,” and variations of thereof, shall not be deemed
to be terms of limitation, but rather shall be deemed to be followed by the words “without
limitation.” The parties acknowledge that they have been represented by counsel and have had the
opportunity to conduct due diligence.

     10.12 Third Parties. None of the provisions of this Agreement shall be for the
benefit of or enforceable by any Third Party.

     10.13 Affiliates. The rights and obligations of each party shall apply to its
Affiliates, provided that each party shall be fully responsible for the performance by its
Affiliates of such party’s obligations under this Agreement.

     10.14 Counterparts. This Agreement may be executed in two or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute one and the same
instrument.

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

27

 

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.

	 	 	 	 	 
	 	PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

 	 
	 	By  	/s/ Hugh Martin
 	 
	 	 	Hugh Martin, PhD. 	 
	 	 	Chairman and Chief Executive Officer 	 
	 
	 	GEN-PROBE INCORPORATED

 	 
	 	By  	/s/ Eric Tardif
 	 
	 	 	Eric Tardif 	 
	 	 	Senior Vice President, Corporate Strategy 	 
	 

28

 

EXHIBIT LIST

A  —  Initial Development Plan

B  —  Initial Appointees to Steering Committee

C  —  V2 Proof of Concept Criteria

29

 

EXHIBIT A

INITIAL DEVELOPMENT PLAN

The parties shall undertake the following activities:

	•	 	making available, through the Steering Committee, all data, expertise, technology and
know-how reasonably necessary for each party to perform its respective obligations under the
Collaboration;

	•	 	defining a potential pilot study regarding the evaluation of Gen-Probe’s Front-End Sample
Preparation technologies combined with PacBio’s sequencing Sample Preparation technologies
across multiple sample sources, with the goals of streamlining and optimizing Sample
Preparation methodologies within the context of current market, regulatory and reimbursement
requirements and developing the Products for the Diagnostics market;

	•	 	identifying, through the Steering Committee, regulatory and reimbursement requirements for
an integrated Sample Preparation and Third Generation Sequencing System;

	•	 	identifying the other expected requirements of the Products, including workflow, cost,
performance and other requirements, in each case based in part on customer and key opinion
leader input; and

	•	 	identifying and planning strategies for ensuring clinical adoption of the Products.

30

 

EXHIBIT B

INITIAL APPOINTEES TO STEERING COMMITTEE

Gen-Probe Incorporated

	1.	 	[...***...]

	2.	 	[...***...]

	3.	 	[...***...]

Pacific Biosciences, Inc.

	1.	 	[...***...]

	2.	 	[...***...]

	3.	 	[...***...]

***Confidential Treatment Requested

31

 

EXHIBIT C

V2 PROOF OF CONCEPT CRITERIA

“V2 Proof of Concept” shall mean PacBio’s initial demonstration, currently targeted to be
completed in [...***...], that the V2 System is [...***...], including [...***...], [...***...] and satisfaction of
the milestones set forth below:

	1.	 	Completion of [...***...], including:

	 	a.	 	Successful completion of [...***...].
	 
	 	b.	 	Completion of [...***...].
	 
	 	c.	 	Completion of the preliminary [...***...], which shall outline the future
development pathway and identify any significant remaining technical challenges and
the proposed resolution of such challenges.
	 
	 	d.	 	Successful completion of tests on [...***...] and [...***...], demonstrating
preliminary feasibility. Such feasibility tests should address at least the
following risk items: [...***...].

	2.	 	Successful completion of the preliminary cost analysis of the [...***...] and its manufacture,
according to the then-current design of the [...***...] and V2 System, demonstrating reasonable
technical and commercial efficacy and feasibility of such product for its intended
application.

	3.	 	Successful completion of the intellectual property portfolio strategy and plan, including
[...***...].

	4.	 	Completion of risk analysis identifying technical and commercial risks and severity, together
with a mitigation plan.

	5.	 	Completion of feasibility for the V2 System as a whole, including top level architecture.

***Confidential Treatment Requested

32exv10w2

Exhibit 10.2

***Text Omitted and Filed Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(b)(4)

and 240.24b-2.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

SERIES F PREFERRED STOCK PURCHASE AGREEMENT

June 16, 2010

 

 

TABLE OF CONTENTS

	 	 	 	 	 
	 	 	Page
	1. AGREEMENT TO SELL AND PURCHASE
	 	 	1	 
	1.1 Authorization of Shares
	 	 	1	 
	1.2 Sale and Purchase
	 	 	1	 
	 
	2. CLOSING, DELIVERY AND PAYMENT
	 	 	1	 
	2.1 Closing
	 	 	1	 
	2.2 Delivery
	 	 	2	 
	 
	3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY
	 	 	2	 
	3.1 Organization, Good Standing and Qualification
	 	 	2	 
	3.2 Subsidiaries
	 	 	2	 
	3.3 Capitalization; Voting Rights
	 	 	3	 
	3.4 Authorization; Binding Obligations
	 	 	4	 
	3.5 Financial Statements
	 	 	5	 
	3.6 Liabilities
	 	 	5	 
	3.7 Agreements; Action
	 	 	5	 
	3.8 Obligations to Related Parties
	 	 	6	 
	3.9 Changes
	 	 	6	 
	3.10 Title to Properties and Assets; Liens, Etc.
	 	 	7	 
	3.11 Intellectual Property
	 	 	7	 
	3.12 Compliance with Other Instruments
	 	 	8	 
	3.13 Litigation
	 	 	9	 
	3.14 Tax Returns and Payments
	 	 	9	 
	3.15 Employees
	 	 	9	 
	3.16 Registration Rights and Voting Rights
	 	 	10	 
	3.17 Compliance with Laws; Permits
	 	 	10	 
	3.18 Offering Valid
	 	 	10	 
	3.19 Minute Books
	 	 	11	 
	3.20 Real Property Holding Corporation
	 	 	11	 
	3.21 Disclosure
	 	 	11	 
	3.22 Employee Benefit Plans
	 	 	11	 
	3.23 Employee Relations to Management
	 	 	11	 
	3.24 Environmental and Safety Laws
	 	 	11	 
	3.25 Insurance
	 	 	11	 
	3.26 No Restricted Persons
	 	 	11	 
	 
	4. REPRESENTATIONS AND WARRANTIES OF PURCHASERS
	 	 	12	 
	4.1 Requisite Power and Authority
	 	 	12	 
	4.2 Investment Representations
	 	 	12	 
	4.3 Transfer Restrictions
	 	 	14	 

 

 

TABLE OF CONTENTS

(Continued)

	 	 	 	 	 
	 	 	Page
	5. CONDITIONS TO CLOSING
	 	 	14	 
	5.1 Conditions to Purchasers’ Obligations at the Initial Closing
	 	 	14	 
	5.2 Conditions to Obligations of the Company
	 	 	15	 
	 
	6. MISCELLANEOUS
	 	 	16	 
	6.1 Governing Law
	 	 	16	 
	6.2 Survival
	 	 	16	 
	6.3 Successors and Assigns
	 	 	16	 
	6.4 Entire Agreement
	 	 	17	 
	6.5 Severability
	 	 	17	 
	6.6 Amendment and Waiver
	 	 	17	 
	6.7 Delays or Omissions
	 	 	17	 
	6.8 Waiver of Conflicts
	 	 	17	 
	6.9 Notices
	 	 	18	 
	6.10 Expenses
	 	 	18	 
	6.11 Attorneys’ Fees
	 	 	19	 
	6.12 Titles and Subtitles
	 	 	19	 
	6.13 Counterparts
	 	 	19	 
	6.14 Broker’s Fees
	 	 	19	 
	6.15 Exculpation Among Purchasers
	 	 	19	 
	6.16 Rights of Purchasers
	 	 	19	 
	6.17 No Commitment for Additional Financing
	 	 	19	 
	6.18 Pronouns
	 	 	20	 
	6.19 California Corporate Securities Law
	 	 	20	 

-ii-

 

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

SERIES F PREFERRED STOCK PURCHASE AGREEMENT

     THIS SERIES F PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into
as of June 16, 2010, by and among PACIFIC BIOSCIENCES OF CALIFORNIA, INC., a Delaware corporation
(the “Company”), and each of those persons and entities, severally and not jointly, whose names are
set forth on the Schedule of Purchasers attached hereto as Exhibit A (which persons and
entities are hereinafter collectively referred to as “Purchasers” and each individually as a
“Purchaser”).

     THE PARTIES HEREBY AGREE AS FOLLOWS:

     1. AGREEMENT TO SELL AND PURCHASE

          1.1 Authorization of Shares. The Company has authorized (a) the sale and issuance to
Purchasers of up to an aggregate of [...***...] shares of its Series F Preferred Stock (the
“Shares”) and (b) the shares of Junior Preferred Stock and Common Stock issuable upon conversion of
the shares of Series F Preferred Stock and the shares of Common Stock issuable upon conversion of
any such shares of Junior Preferred Stock (the “Conversion Shares”). The Shares and the Conversion
Shares have the rights, preferences, privileges and restrictions set forth in the Amended and
Restated Certificate of Incorporation of the Company, in the form attached hereto as Exhibit
B (the “Restated Charter”).

          1.2 Sale and Purchase. Subject to the terms and conditions hereof, at the Closing (as
hereinafter defined) the Company hereby agrees to issue and sell to each Purchaser, severally and
not jointly, and each Purchaser agrees to purchase from the Company, severally and not jointly, the
number of Shares set forth opposite such Purchaser’s name on Exhibit A, at a purchase price
of [...***...] ($[...***...]) per share.

     2. CLOSING, DELIVERY AND PAYMENT.

          2.1 Closing.

               (a) The purchase, sale and issuance of the shares shall take place at one or more closings
(each of which is referred to in this Agreement as a “Closing”). The initial Closing of the sale
and purchase of the Shares under this Agreement (the “Initial Closing”) shall take place at 1:00
p.m. local time on the date hereof, at the offices of Wilson Sonsini Goodrich & Rosati,
Professional Corporation, 650 Page Mill Road, Palo Alto, California, 94304 or at such other time or
place as the Company and Purchasers may mutually agree.

               (b) If less than all of the Shares are sold and issued at the Initial Closing, then, subject
to the terms and conditions of this Agreement, the Company may sell and issue at one or more
subsequent Closings (each, a “Subsequent Closing”), within 90 days after the Initial Closing,

***Confidential Treatment Requested

1

 

up to the balance of the unissued Shares to such persons or entities as may be approved by the
Company. Any such sale and issuance in a Subsequent Closing shall be on the same terms and
conditions as those contained herein, and such persons or entities shall, upon execution and
delivery of the relevant signature pages, become parties to, and be bound by, this Agreement, the
Fifth Amended and Restated Investor Rights Agreement in substantially the form attached hereto as
Exhibit C (the “Investor Rights Agreement”), the Fifth Amended and Restated Right of First
Refusal and Co-Sale Agreement in substantially the form attached hereto as Exhibit D (the
“Co-Sale Agreement”), and the Fifth Amended and Restated Voting Agreement in substantially the form
attached hereto as Exhibit E (the “Voting Agreement,” and together with this Agreement, the
Co-Sale Agreement and the Investor Rights Agreement, the “Related Agreements”), without the need
for an amendment to any of the Related Agreements except to add such person’s or entity’s name to
the appropriate exhibit to such Related Agreements, and shall have the rights and obligations
hereunder and thereunder, in each case as of the date of the applicable Subsequent Closing. The
Company will promptly furnish to each Purchaser copies of the amended exhibits referred to in the
preceding sentence. Each Subsequent Closing shall take place at such date, time and place as shall
be approved by the Company in its sole discretion.

          2.2 Delivery. At each Closing, subject to the terms and conditions hereof, the Company will
deliver to each Purchaser a certificate representing the number of Shares to be purchased at the
Closing by such Purchaser, against payment of the purchase price therefor by check, wire transfer
made payable to the order of the Company, cancellation or conversion of indebtedness or any
combination of the foregoing, [...***...].

     3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

     Except as set forth on a Schedule of Exceptions delivered by the Company to Purchasers at the
applicable Closing, the Company hereby represents and warrants to each Purchaser as follows:

          3.1 Organization, Good Standing and Qualification. The Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of Delaware. The
Company has all requisite corporate power and authority to conduct its business, own and operate
its properties and assets, to execute and deliver this Agreement and the Investor Rights Agreement,
Co-Sale Agreement and Voting Agreement, to issue and sell the Shares and the Conversion Shares, and
to carry out the provisions of this Agreement, the Related Agreements and the Restated Charter and
to carry on its business as presently conducted and as proposed to be conducted. The Company is
duly qualified to do business and is in good standing as a foreign corporation in all jurisdictions
in which the nature of its activities and of its properties (both owned and leased) makes such
qualification necessary, except for those jurisdictions in which failure to do so would not have a
material adverse effect on the Company or its business, properties, assets or financial condition.

          3.2 Subsidiaries. The Company does not own or control any equity security or other interest
of any other corporation, limited partnership or other business entity. The Company is not a
participant in any joint venture, partnership or similar arrangement. Since its inception, the

***Confidential Treatment Requested

2

 

Company has not consolidated or merged with, acquired all or substantially all of the assets
of, or acquired the stock of or any interest in any corporation, partnership, association, or other
business entity.

          3.3 Capitalization; Voting Rights.

               (a) The authorized capital stock of the Company, immediately prior to the Initial Closing,
consists of (i) 121,668,835 shares of Common Stock, par value $0.0001 per share,
[...***...] of which are issued and outstanding, (ii) 153,394,052
shares of Preferred Stock, par value $0.0001 per share, 5,405,992 of which are designated Series A
Preferred Stock, [...***...] of which are issued and outstanding, (iii) 3,530,768 shares of Series B
Preferred Stock, par value $0.0001 per share, [...***...] shares of which are issued and outstanding,
(iv) 5,342,197 shares of Series C Preferred Stock, par value $0.0001 per share, [...***...] of which
are issued and outstanding, (v) 12,525,000 shares of Series D Preferred Stock, [...***...] of which are
issued and outstanding, (vi) 26,866,790 shares of Series E Preferred Stock, [...***...] of which are
issued and outstanding, (vii) 19,659,240 shares of Series F Preferred Stock, [...***...] of which are
issued and outstanding, and (viii) 80,064,065 shares of Junior Preferred Stock, [...***...] shares of
which are issued and outstanding. Attached to this Agreement as Exhibit G is a complete
list of all stockholders, option holders, warrant holders, convertible note holders and other
security holders of the Company (and their respective holdings) as of immediately prior to the
Closing.

               (b) Under the Company’s 2004 Equity Incentive Plan (the “2004 Plan”), (i) [...***...] shares of
Junior Preferred Stock have been issued pursuant to restricted stock purchase agreements and/or the
exercise of outstanding options and are included in 3.3(a)(viii) above, (ii) options to purchase
[...***...] shares of Junior Preferred Stock are currently outstanding, and (iii) [...***...] options to
purchase shares of Junior Preferred Stock remain available for future issuance to officers,
directors, employees and consultants of the Company under the 2004 Plan.

               (c) Under the Company’s 2005 Equity Incentive Plan (the “2005 Plan,” together with the 2004
Plan, the “Plans”), (i) [...***...] shares of Common Stock are currently outstanding pursuant to
restricted stock purchase agreements and/or the exercise of outstanding options and are included in
3.3(a)(i) above, (ii) [...***...] options to purchase shares of Common Stock are currently outstanding,
and (iii) [...***...] shares of Common Stock remain available for future issuance to officers,
directors, employees and consultants of the Company.

               (d) Other than the shares reserved for issuance under the Plans and except as may be granted
pursuant to this Agreement and the Related Agreements, there are no outstanding options, warrants,
rights (including conversion or preemptive rights and rights of first refusal), proxy or
stockholder agreements, or agreements of any kind for the purchase or acquisition from the Company
of any of its securities.

               (e) All issued and outstanding shares of the Company’s Common Stock and Preferred Stock (i)
have been duly authorized and validly issued and are fully paid and nonassessable, (ii) were issued
in compliance with all applicable state and federal laws concerning

***Confidential Treatment Requested

3

 

the issuance of securities and (iii) solely with respect to the Common Stock or Junior
Preferred Stock not issued upon the conversion of Preferred Stock, are subject to a right of first
refusal in favor of the Company upon transfer.

               (f) The rights, preferences, privileges and restrictions of the Shares and the Conversion
Shares are as stated in the Restated Charter. The Conversion Shares have been duly and validly
reserved for issuance. When issued in compliance with the provisions of this Agreement and the
Restated Charter, the Shares and the Conversion Shares will be validly issued, fully paid and
nonassessable, and will be free of any liens or encumbrances other than liens and encumbrances
created by or imposed by Purchasers; provided, however, that the Shares and the Conversion Shares
may be subject to restrictions on transfer under state and/or federal securities laws as set forth
herein or as otherwise required by such laws at the time a transfer is proposed.

               (g) All options granted and Common Stock or Junior Preferred Stock issued (other than upon
conversion of Preferred Stock) vest as follows: twenty-five percent (25%) of the shares vest one
(1) year following the vesting commencement date, with the remaining seventy-five percent (75%)
vesting in equal monthly installments over the three (3) years following the anniversary of the
vesting commencement date. No stock plan, stock purchase, stock option or other agreement or
understanding between the Company and any holder of any equity securities or rights to purchase
equity securities provides for acceleration or other changes in the vesting provisions or other
terms of such agreement or understanding as the result of (i) termination of employment or
consulting services (whether actual or constructive); (ii) any merger, consolidated sale of stock
or assets, change in control or any other transaction(s) by the Company; or (iii) the occurrence of
any other event or combination of events.

               (h) All outstanding shares of Common Stock and Preferred Stock, and all shares of Common Stock
and Preferred Stock issuable upon the exercise or conversion of outstanding options, warrants or
other exercisable or convertible securities are subject to a market standoff or “lockup” agreement
of not less than 180 days following the Company’s initial public offering.

          3.4 Authorization; Binding Obligations. All corporate action on the part of the Company and
its directors and stockholders necessary for the authorization of this Agreement and the Related
Agreements, the performance of all obligations of the Company hereunder and thereunder at the
Closing and the authorization, sale, issuance and delivery of the Shares pursuant hereto and the
Conversion Shares pursuant to the Restated Charter has been taken. The Agreement and the Related
Agreements, when executed and delivered, will be valid and binding obligations of the Company
enforceable in accordance with their terms, except (a) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium or other laws of general application affecting enforcement
of creditors’ rights, (b) general principles of equity that restrict the availability of equitable
remedies, and (c) to the extent that the enforceability of the indemnification provisions in the
Investor Rights Agreement may be limited by applicable laws. The sale of the Shares and the
subsequent conversion of the Shares into Conversion Shares are not and will not be subject to any
preemptive rights or rights of first refusal that have not been properly waived or complied with.

4

 

          3.5 Financial Statements. The Company has made available to each Purchaser its unaudited
balance sheet as at December 31, 2009 (the “Statement Date”) and unaudited consolidated statements
of income and cash flows for the 12-month period ending on the Statement Date (collectively, the
“Financial Statements”). The Financial Statements, together with the notes thereto, have been
prepared in accordance with generally accepted accounting principles applied on a consistent basis
throughout the periods indicated, except as disclosed therein, and present fairly the financial
condition and position of the Company as of the Statement Date; provided, however, that the
Financial Statements are subject to year-end audit adjustments (which are not expected to be
material either individually or in the aggregate), and do not contain all footnotes required under
generally accepted accounting principles.

          3.6 Liabilities. The Company has no material liabilities, contingent or otherwise, not
disclosed in the Financial Statements, except current liabilities incurred in the ordinary course
of business subsequent to the Statement Date which have not been, either in any individual case or
in the aggregate, material to the financial condition or operation of the Company. The Company
maintains and will continue to maintain a standard system of accounting established and
administered in accordance with generally accepted accounting principles.

          3.7 Agreements; Action.

               (a) Except for agreements explicitly contemplated hereby and agreements between the Company
and its employees with respect to the sale of the Company’s Common Stock pursuant to the Plans,
there are no agreements, understandings or proposed transactions between the Company and any of its
officers, directors, employees, affiliates or any affiliate thereof.

               (b) There are no agreements, understandings, instruments, contracts, proposed transactions,
judgments, orders, writs or decrees to which the Company is a party or by which it is bound which
may involve (i) future obligations (contingent or otherwise) of, or payments to, the Company in
excess of $50,000, or (ii) the transfer or license of any patent, copyright, trade secret or other
proprietary right to or from the Company (other than licenses by the Company of “off the shelf” or
other standard products, each of which agreements are not, individually, material to the Company’s
business), (iii) provisions restricting or affecting the development, manufacture or distribution
of the Company’s products or services, or (iv) indemnification by the Company with respect to
infringements of proprietary rights (other than indemnification obligations arising from purchase,
sale or license agreements entered into in the ordinary course of business).

               (c) The Company has not (i) declared or paid any dividends, or authorized or made any
distribution upon or with respect to any class or series of its capital stock, (ii) incurred or
guaranteed any indebtedness for money borrowed or any other liabilities (other than with respect to
dividend obligations, distributions, indebtedness and other obligations incurred in the ordinary
course of business or as disclosed in the Financial Statements) individually in excess of $25,000
or, in the case of indebtedness and/or liabilities individually less than $25,000, in excess of
$50,000 in the aggregate, (iii) made any loans or advances to any person, other than ordinary
advances for travel

5

 

expenses, or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other
than the sale of its inventory in the ordinary course of business.

               (d) For the purposes of subsections (b) and (c) above, all indebtedness, liabilities,
agreements, understandings, instruments, contracts and proposed transactions involving the same
person or entity (including persons or entities the Company has reason to believe are affiliated
therewith) shall be aggregated for the purpose of meeting the individual minimum dollar amounts of
such subsections.

          3.8 Obligations to Related Parties. There are no obligations of the Company to officers,
directors, stockholders, or employees of the Company other than (a) for payment of salary for
services rendered, (b) reimbursement for reasonable expenses incurred on behalf of the Company and
(c) for other standard employee benefits made generally available to all employees (including stock
option agreements outstanding under any stock option plan approved by the Board of Directors of the
Company).

          3.9 Changes. Since the Statement Date, there has not been:

               (a) Any change in the assets, liabilities, financial condition or operations of the Company
from that reflected in the Financial Statements, other than changes in the ordinary course of
business, none of which individually or in the aggregate has had a material adverse effect on such
assets, liabilities, financial condition or operations of the Company;

               (b) Any resignation or termination of any officer, key employee or group of employees of the
Company;

               (c) Any material change, except in the ordinary course of business, in the contingent
obligations of the Company by way of guaranty, endorsement, indemnity, warranty or otherwise;

               (d) Any damage, destruction or loss, whether or not covered by insurance, materially and
adversely affecting the assets, properties, business or financial condition of the Company, or that
would reasonably be expected to materially and adversely affect the prospects of the Company;

               (e) Any waiver by the Company of a valuable right or of a material debt owed to it;

               (f) Any material change in any compensation arrangement or agreement with any employee,
officer, director or stockholder;

               (g) Any labor organization activity related to the Company;

               (h) Any sale, assignment, or exclusive license or transfer of any patents, trademarks,
copyrights, trade secrets or other intangible assets;

6

 

               (i) Any change in any agreement to which the Company is a party or by which it is bound which
materially and adversely affects the business, assets, liabilities, financial condition or
operations of the Company, or that would reasonably be expected to materially and adversely affect
the prospects of the Company;

               (j) Any other event or condition of any character that, either individually or cumulatively,
has materially and adversely affected the business, assets, liabilities, financial condition or
operations of the Company; or

               (k) Any arrangement or commitment by the Company to do any of the acts described in subsection
(a) through (j) above.

          3.10 Title to Properties and Assets; Liens, Etc. The Company has good and marketable title
to its properties and assets, including the properties and assets reflected in the most recent
balance sheet included in the Financial Statements, and good title to its leasehold estates, in
each case subject to no mortgage, pledge, lien, lease, encumbrance or charge, other than (a) those
resulting from taxes which have not yet become delinquent, (b) minor liens and encumbrances which
do not materially detract from the value of the property subject thereto or materially impair the
operations of the Company, and (c) those that have otherwise arisen in the ordinary course of
business and do not materially impair the Company’s use and ownership of such property and assets.
The Company is in compliance with all material terms of each lease to which it is a party or is
otherwise bound. The Company’s properties and assets are in good condition and repair in all
material respects, normal wear and tear excepted.

          3.11 Intellectual Property.

               (a) To the best of its knowledge, the Company owns or possesses sufficient legal rights to all
patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information
and other proprietary rights and processes necessary for its business as now conducted and as
presently proposed to be conducted, without any known infringement of the rights of others. There
are no outstanding options, licenses or agreements of any kind relating to the foregoing
proprietary rights to which the Company is a party, nor is the Company bound by or a party to any
options, licenses or agreements of any kind with respect to the patents, trademarks, service marks,
trade names, copyrights, trade secrets, licenses, information and other proprietary rights and
processes of any other person or entity other than such licenses or agreements arising from the
purchase of “off the shelf” or standard products.

               (b) The Company has not received any communications alleging that the Company has violated or,
by conducting its business as presently proposed, would violate any of the patents, trademarks,
service marks, trade names, copyrights or trade secrets or other proprietary rights of any other
person or entity, nor is the Company aware of any basis therefor that has not previously been
disclosed to the Purchasers. To the Company’s knowledge, the Company has not violated any of the
patents, trademarks, service marks, trade names, copyrights or trade secrets of any other person or
entity.

7

 

               (c) The Company is not aware that any of its employees is obligated under any contract
(including licenses, covenants or commitments of any nature) or other agreement, or subject to any
judgment, decree or order of any court or administrative agency, that would interfere with their
duties to the Company or that would conflict with the Company’s business as proposed to be
conducted. Each current and former employee, officer and consultant of the Company has executed a
proprietary information and inventions agreement in the form(s) as delivered to Purchasers. No
current or former employee, officer or consultant of the Company has excluded works or inventions
made prior to his or her employment with the Company from his or her assignment of inventions
pursuant to such employee, officer or consultant’s proprietary information and inventions
agreement. Neither the execution nor delivery of this Agreement or the Related Agreements, or any
amendments thereto, nor the carrying on of the Company’s business by the employees of the Company,
nor the conduct of the Company’s business, will, to the best of the Company’s knowledge, conflict
with or result in a breach of the terms, conditions or provisions of, or constitute a default
under, any contract, covenant or instrument under which any of such employees is now obligated. To
the Company’s knowledge, no employee or officer of the Company has used any patents, trademarks,
service marks, trade names, copyrights or trade secrets (collectively, the “Intellectual Property”)
of a third party (including, without limitation, development of any Company Intellectual Property).
The Company does not believe it is or will be necessary to utilize any Intellectual Property of
any of its employees (or people it currently intends to hire) made prior to their employment by the
Company, and at present no such employee Intellectual Property forms a part of any Company
Intellectual Property except that which has already been assigned to the Company by its employees
or the Cornell Research Foundation, Inc. The Schedule of Exceptions contains a complete list of
patents and pending and provisional patent applications owned by or exclusively licensed to the
Company. The Company has taken reasonable steps to protect and preserve the confidentiality of all
confidential, non-public information desired to be kept confidential by the Company.

          3.12 Compliance with Other Instruments. The Company is not in violation or default of any
term of its charter documents, each as amended, or of any provision of any mortgage, indenture,
contract, agreement, instrument or contract to which it is party or by which it or any of its
assets or properties is bound or of any judgment, decree, order or writ other than any such
violation that would not have a material adverse effect on the Company, its business, properties,
assets or financial condition. The execution, delivery, and performance of and compliance with
this Agreement, and the Related Agreements, and the issuance and sale of the Shares pursuant hereto
and of the Conversion Shares pursuant to the Restated Charter, will not, with or without the
passage of time or giving of notice, result in any such material violation, or be in conflict with
or constitute a material default under any such term, or result in the creation of any mortgage,
pledge, lien, encumbrance or charge upon any of the properties or assets of the Company or the
suspension, revocation, impairment, forfeiture or nonrenewal of any permit, license, authorization
or approval applicable to the Company, its business or operations or any of its assets or
properties. To its knowledge, the Company has not performed any act, nor does any condition exist,
the occurrence or existence of which would result in the Company’s loss of any right granted under
any license, distribution agreement or other agreement required to be disclosed on the Schedule of
Exceptions.

8

 

          3.13 Litigation. There is no action, suit, proceeding or investigation pending or, to the
Company’s knowledge, currently threatened in writing against the Company that questions the
validity of this Agreement, the Related Agreements or the right of the Company to enter into any of
such agreements, or to consummate the transactions contemplated hereby or thereby, or which would
reasonably be expected to result, either individually or in the aggregate, in any material adverse
effect on the Company, or the business, properties, assets, condition or affairs of the Company,
financially or otherwise, or any change in the current equity ownership of the Company, nor is the
Company aware that there is any basis for any of the foregoing. The foregoing includes, without
limitation, actions pending or, to the Company’s knowledge, threatened in writing involving the
prior employment of any of the Company’s employees, their use in connection with the Company’s
business of any information or techniques allegedly proprietary to any of their former employers,
or their obligations under any agreements with prior employers. The Company is not a party or to
its knowledge subject to the provisions of any order, writ, injunction, judgment or decree of any
court or government agency or instrumentality. There is no action, suit, proceeding or
investigation by the Company currently pending or which the Company intends to initiate.

          3.14 Tax Returns and Payments. The Company is and always has been a subchapter C corporation.
The Company has filed all tax returns (federal, state and local) required to be filed by it and
such returns are true and correct in all material respects. All taxes shown to be due and payable
on such returns, any assessments imposed, and to the Company’s knowledge all other taxes due and
payable by the Company on or before the Closing, have been paid or will be paid prior to the time
they become delinquent. The Company has no knowledge of any liability of any tax to be imposed
upon its properties or assets as of the date of this Agreement that is not adequately provided for.
The Company has not been advised (a) that any of its returns, federal, state or local, have been
or are being audited as of the date hereof, or (b) of any deficiency in assessment or proposed
adjustment to its federal, state or local taxes.

          3.15 Employees. The Company is not a party to nor bound by any currently effective employment
contract, deferred compensation arrangement, bonus plan, incentive plan, profit sharing plan,
retirement agreement or other employee compensation plan or agreement. The Company has no
collective bargaining agreements with any of its employees. Subject to applicable law, the
employment of each officer and employee of the Company is terminable at the will of the Company.
To the Company’s knowledge, no employee of the Company, nor any consultant with whom the Company
has contracted, is in violation of any term of any employment contract, proprietary information
agreement or any other agreement relating to the right of any such individual to be employed by, or
to contract with, the Company; and to the Company’s knowledge the continued employment by the
Company of its present employees, and the performance of the Company’s contracts with its
independent contractors, will not result in any such violation. The Company has not received any
notice alleging that any such violation has occurred. No employee of the Company has been granted
the right to continued employment by the Company or to any material compensation following
termination of employment with the Company. The Company is not aware that any officer, key
employee or group of employees intends to terminate his, her or their employment with the Company,
nor does the Company have a present intention to terminate the employment of any officer, key
employee or group of employees. There are no actions pending, or

9

 

to the Company’s knowledge, threatened, by any former or current employee concerning such
person’s employment by the Company. To the best of its knowledge, the Company has complied in all
material respects with all applicable state and federal laws and regulations respecting employment
and employment practices, terms and conditions of employment, wages and hours and other laws
related to employment, and there are no arrears in the payment of wages, withholding or social
security taxes, unemployment insurance premiums or other similar obligation.

          3.16 Registration Rights and Voting Rights. Except as required pursuant to the Investor
Rights Agreement, the Company is presently not under any obligation, and has not granted any
rights, to register (as defined in Section 1.1 of the Investor Rights Agreement) any of the
Company’s presently outstanding securities or any of its securities that may hereafter be issued.
To the Company’s knowledge, except as contemplated in the Voting Agreement, no stockholder of the
Company has entered into any agreement with respect to the voting of equity securities of the
Company.

          3.17 Compliance with Laws; Permits. The Company is not in violation of any applicable
statute, rule, regulation, order or restriction of any domestic or foreign government or any
instrumentality or agency thereof in respect of the conduct of its business or the ownership of its
properties which violation would materially and adversely affect the business, assets, liabilities,
financial condition or operations of the Company or which could reasonably be expected to
materially and adversely affect the Company’s prospects. No United States domestic governmental
orders, permissions, consents, approvals or authorizations are required to be obtained and no
registrations or declarations are required to be filed in connection with the execution and
delivery of this Agreement or the Related Agreements or the issuance of the Shares or the
Conversion Shares, except such as have been duly and validly obtained or filed, or with respect to
any filings that must be made after the Closing, as will be filed in a timely manner. The Company
has all franchises, permits, licenses and any similar authority necessary for the conduct of its
business as now being conducted by it, the lack of which could materially and adversely affect the
business, properties or financial condition of the Company or which could reasonably be expected to
materially and adversely affect the Company’s prospects and believes it can obtain, without undue
burden or expense, any similar authority for the conduct of its business as planned to be
conducted. The Company is not in default in any material respect under any of such franchises,
permits, licenses or other similar authority.

          3.18 Offering Valid. Assuming the accuracy of the representations and warranties of
Purchasers contained in Section 4.2 hereof, the offer, sale and issuance of the Shares and the
Conversion Shares will be exempt from the registration requirements of the Securities Act of 1933,
as amended (the “Securities Act”), and will have been registered or qualified (or are exempt from
registration and qualification) under the registration, permit or qualification requirements of all
applicable state securities laws. Neither the Company nor any agent on its behalf has solicited or
will solicit any offers to sell or has offered to sell or will offer to sell all or any part of the
Shares to any person or persons so as to bring the sale of such Shares by the Company within the
registration provisions of the Securities Act or any state securities laws.

10

 

          3.19 Minute Books. The minute books of the Company made available to Purchasers who have
requested the same contain a complete summary of all meetings of directors and stockholders since
the time of incorporation.

          3.20 Real Property Holding Corporation. The Company is not a real property holding
corporation within the meaning of Section 897(c)(2) of the Internal Revenue Code of 1986, as
amended, and any regulations promulgated thereunder.

          3.21 Disclosure. The Company has provided each Purchaser with all the information that such
Purchaser has requested for deciding whether to purchase the Shares and all information that the
Company believes is reasonably necessary to enable such Purchaser to make such decision. Neither
this Agreement nor any certificate furnished or to be furnished to the Purchasers at the Closing
contains any untrue statement of a material fact or, when taken together, omits to state a material
fact necessary to make the statements herein or therein, in light of the circumstances under which
they were made, not misleading. The Company’s business plan, as delivered to the Purchasers, was
prepared in good faith by the Company. The Company does not represent or warrant that it will
achieve any results projected in such business plan.

          3.22 Employee Benefit Plans. The Company does not have any Employee Benefit Plan as defined
in the Employee Retirement Income Security Act of 1974.

          3.23 Employee Relations to Management. To its knowledge, no member of the Company’s
management is related by blood, marriage, legal adoption, guardianship or other legally authorized
custodial relationship to any Board member or employee of the Company.

          3.24 Environmental and Safety Laws. To the Company’s knowledge, the Company is not in
violation of any applicable statute, law or regulation relating to the environment or occupational
health and safety, and to the Company’s knowledge, no material expenditures are or will be required
in order to comply with any current environmental and safety statute, law or regulation.

          3.25 Insurance. The Company has in full force and effect general commercial, fire, casualty
insurance, products liability and errors and omissions policies with coverage sufficient in amount
it believes to allow it to replace any of its properties that could be damaged or destroyed and
customary for companies similarly situated (as to business and financial resources) to the Company.

          3.26 No Restricted Persons. To the Company’s knowledge, no officer, director or employee of
the Company is identified on any of the following documents: (1) the Office of Foreign Assets
Control of the United States Department of the Treasury list of “Specially Designated Nationals and
Blocked Persons” (“SDNs”); (2) the Bureau of Industry and Security of the United States Department
of Commerce “Denied Persons List,” “Entity List” or “Unverified List”; (3) the Office of Defense
Trade Controls of the United States Department of State “List of Debarred Parties”; (4) the
Financial Sanctions Unit of the Bank of England “Consolidated List”; (5) the

11

 

Solicitor General of Canada’s “Anti-Terrorism Act Listed Entities”; (6) the Australian
Department of Foreign Affairs and Trade “Charter of the United Nations (Anti-terrorism — Persons
and Entities) List”; (7) the United Nations Security Council Counter-Terrorism Committee
“Consolidated List”; or (8) European Union Commission Regulation No. 1996/2001 of October 11, 2001.
The Company is not involved in business arrangements or otherwise engages in transactions with or
involving countries subject to economic or trade sanctions imposed by the United States Government,
or with or involving SDNs or Cuban nationals in violation of the regulations maintained by OFAC.

     4. REPRESENTATIONS AND WARRANTIES OF PURCHASERS.

     Each Purchaser hereby represents and warrants to the Company, severally and not jointly, as
follows (provided that such representations and warranties do not lessen or obviate the
representations and warranties of the Company set forth in this Agreement):

          4.1 Requisite Power and Authority. Purchaser has all necessary power and authority to execute
and deliver this Agreement and the Related Agreements and to carry out their provisions. All
action on Purchaser’s part required for the lawful execution and delivery of this Agreement and the
Related Agreements has been taken. Upon their execution and delivery, this Agreement and the
Related Agreements will be valid and binding obligations of Purchaser, enforceable in accordance
with their terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization,
moratorium or other laws of general application affecting enforcement of creditors’ rights, (b) as
limited by general principles of equity that restrict the availability of equitable remedies, and
(c) to the extent that the enforceability of the indemnification provisions of the Investor Rights
Agreement may be limited by applicable laws.

          4.2 Investment Representations. Purchaser understands that neither the Shares nor the
Conversion Shares have been registered under the Securities Act. Purchaser also understands that
the Shares are being offered and sold pursuant to an exemption from registration contained in the
Securities Act based in part upon Purchaser’s representations contained in the Agreement.
Purchaser hereby represents and warrants as follows:

               (a) Purchaser Bears Economic Risk. Purchaser has substantial experience in evaluating and
investing in private placement transactions of securities in companies similar to the Company so
that it is capable of evaluating the merits and risks of its investment in the Company and has the
capacity to protect its own interests. Purchaser must bear the economic risk of this investment
indefinitely unless the Shares (or the Conversion Shares) are registered pursuant to the Securities
Act, or an exemption from registration is available. Purchaser understands that the Company has no
present intention of registering the Shares, the Conversion Shares or any shares of its Common
Stock. Purchaser also understands that there is no assurance that any exemption from registration
under the Securities Act will be available and that, even if available, such exemption may not
allow Purchaser to transfer all or any portion of the Shares or the Conversion Shares under the
circumstances, in the amounts or at the times Purchaser might propose.

12

 

               (b) Acquisition for Own Account. Purchaser is acquiring the Shares and the Conversion Shares
for Purchaser’s own account or for the account of its clients as an investment advisor for
investment only, and not with a view towards their distribution.

               (c) Purchaser Can Protect Its Interest. Purchaser represents that by reason of its, or of its
management’s, business or financial experience, Purchaser has the capacity to protect its own
interests in connection with the transactions contemplated in this Agreement, and the Related
Agreements. Further, Purchaser is aware of no publication of any advertisement in connection with
the transactions contemplated in the Agreement.

               (d) Accredited Investor. Purchaser represents that it is an accredited investor within the
meaning of Regulation D under the Securities Act.

               (e) Company Information. Purchaser has had an opportunity to discuss the Company’s business,
management and financial affairs with directors, officers and management of the Company and has had
the opportunity to review the Company’s operations and facilities. Purchaser has also had the
opportunity to ask questions of and receive answers from the Company and its management regarding
the terms and conditions of this investment.

               (f) Rule 144. Purchaser acknowledges and agrees that the Shares, and, if issued, the
Conversion Shares are “restricted securities” as defined in Rule 144 promulgated under the
Securities Act as in effect from time to time and must be held indefinitely unless they are
subsequently registered under the Securities Act or an exemption from such registration is
available. Purchaser has been advised or is aware of the provisions of Rule 144, which permits
limited resale of shares purchased in a private placement subject to the satisfaction of certain
conditions, including, among other things: the availability of certain current public information
about the Company, the resale occurring following the required holding period under Rule 144 and
the number of shares being sold during any three-month period not exceeding specified limitations.

               (g) Residence. If Purchaser is an individual, then Purchaser resides in the state or province
identified in the address of Purchaser set forth on Exhibit A; if Purchaser is a
partnership, corporation, limited liability company or other entity, then the office or offices of
Purchaser in which its investment decision was made is located at the address or addresses of
Purchaser set forth on Exhibit A.

               (h) Foreign Investors. If Purchaser is not a United States person (as defined by Section
7701(a)(30) of the Internal Revenue Code of 1986, as amended), Purchaser hereby represents that it
has satisfied itself as to the full observance of the laws of its jurisdiction in connection with
any invitation to subscribe for the Shares or any use of this Agreement, including (i) the legal
requirements within its jurisdiction for the purchase of the Shares, (ii) any foreign exchange
restrictions applicable to such purchase, (iii) any government or other consents that may need to
be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to
the purchase, holding, redemption, sale or transfer of the Shares. The Company’s offer and sale
and

13

 

Purchaser’s subscription and payment for and continued beneficial ownership of the Shares will
not violate any applicable securities or other laws of Purchaser’s jurisdiction.

          4.3 Transfer Restrictions. Each Purchaser acknowledges and agrees that the Shares and, if
issued, the Conversion Shares are subject to restrictions on transfer as set forth in the Investor
Rights Agreement.

     5. CONDITIONS TO CLOSING.

          5.1 Conditions to Purchasers’ Obligations at the Initial Closing. Purchasers’ obligations to
purchase the Shares at a Closing are subject to the satisfaction, at or prior to the date of such
Closing, of the following conditions:

               (a) Representations and Warranties True; Performance of Obligations. The representations and
warranties made by the Company in Section 3 hereof together with the Schedule of Exceptions shall
be true and correct as of the date of such Closing with the same force and effect as if they had
been made as of the date of such Closing, and the Company shall have performed all obligations and
conditions herein required to be performed or observed by it on or prior to the Closing.

               (b) Consents, Permits, and Waivers. The Company shall have obtained any and all consents,
permits and waivers necessary or appropriate for consummation of the transactions contemplated by
the Agreement and the Related Agreements.

               (c) Filing of Restated Charter. The Restated Charter shall have been filed with the Secretary
of State of the State of Delaware and shall continue to be in full force and effect as of the
Closing.

               (d) Corporate Documents. The Company shall have delivered to Purchasers or their counsel,
copies of all corporate documents of the Company as Purchasers shall reasonably request.

               (e) Reservation of Conversion Shares. The Conversion Shares issuable upon conversion of the
Shares shall have been duly authorized and reserved for issuance upon such conversion.

               (f) Compliance Certificate. The Company shall have delivered to Purchasers a Compliance
Certificate, executed by the Chief Executive Officer of the Company, dated the date of such
Closing, to the effect that the conditions specified in subsection (a) of this Section 5.1 have
been satisfied.

               (g) Secretary’s Certificate. Purchasers shall have received from the Company’s Secretary, a
certificate having attached thereto (i) the Company’s Restated Charter as in effect at the time of
the Initial Closing, (ii) the Company’s Bylaws as in effect at the time of the Initial Closing,
(iii) resolutions approved by the Board of Directors authorizing the transactions

14

 

contemplated hereby, (iv) resolutions approved by the Company’s stockholders authorizing the
filing of the Restated Charter, and (v) good standing certificates (including tax good standing)
with respect to the Company from the applicable authority(ies) in Delaware and any other
jurisdiction in which the Company is qualified to do business, dated a recent date before such
Closing.

               (h) Investor Rights Agreement. The Investor Rights Agreement shall have been executed and
delivered by the parties thereto.

               (i) Co-Sale Agreement. The Co-Sale Agreement shall have been executed and delivered by the
parties thereto. The stock certificates representing the outstanding shares subject to the Co-Sale
Agreement shall have been delivered to the Secretary of the Company and shall have had appropriate
legends placed upon them to reflect the restrictions on transfer set forth in the Co-Sale
Agreement.

               (j) Voting Agreement. The Voting Agreement shall have been executed and delivered by the
parties thereto. The stock certificates representing the outstanding shares subject to the Voting
Agreement shall have been delivered to the Secretary of the Company and shall have had appropriate
legends placed upon them to reflect the restrictions on transfer set forth in the Voting Agreement.

               (k) Board of Directors. Upon the Initial Closing, the authorized size of the Board of
Directors of the Company shall be eight members and the Board shall consist of Stephen Turner,
Susan Siegel, William Ericson, Hugh Martin, Brook Byers, Michael Hunkapiller, David Singer and
Randy Livingston.

               (l) Legal Opinion. Purchasers shall have received from legal counsel to the Company an
opinion addressed to them, dated as of the Initial Closing, in substantially the form attached
hereto as Exhibit F.

               (m) Proceedings and Documents. All corporate and other proceedings in connection with the
transactions contemplated at the Initial Closing hereby and all documents and instruments incident
to such transactions shall be reasonably satisfactory in substance and form to Purchasers and their
special counsel, and Purchasers and their special counsel shall have received all such counterpart
originals or certified or other copies of such documents as they may reasonably request.

     5.2 Conditions to Obligations of the Company. The Company’s obligation to issue and sell the
Shares at each Closing is subject to the satisfaction, on or prior to such Closing, of the
following conditions:

               (a) Representations and Warranties True. The representations and warranties in Section 4 made
by those Purchasers acquiring Shares hereof shall be true and correct at the date of the Initial
Closing or the Subsequent Closing, as applicable, with the same force and effect as if they had
been made on and as of said date.

15

 

               (b) Performance of Obligations. Such Purchasers shall have performed and complied with all
agreements and conditions herein required to be performed or complied with by such Purchasers on or
before the applicable Closing.

               (c) Filing of Restated Charter. The Restated Charter shall have been filed with the Secretary
of State of the State of Delaware.

               (d) Investor Rights Agreement. The Investor Rights Agreement shall have been executed and
delivered by Purchasers.

               (e) Co-Sale Agreement. The Co-Sale Agreement shall have been executed and delivered by the
parties thereto.

               (f) Voting Agreement. The Voting Agreement shall have been executed and delivered by the
parties thereto.

               (g) Consents, Permits, and Waivers. The Company shall have obtained any and all consents,
permits and waivers necessary or appropriate for consummation of the transactions contemplated by
the Agreement and the Related Agreements.

     6. MISCELLANEOUS.

               6.1 Governing Law. This Agreement shall be governed by and construed under the laws of the
State of California in all respects as such laws are applied to agreements among California
residents entered into and performed entirely within California, without giving effect to conflict
of law principles thereof.

               6.2 Survival. The representations, warranties, covenants and agreements made herein shall
survive the closing of the transactions contemplated hereby. All statements as to factual matters
contained in any certificate or other instrument delivered by or on behalf of the Company pursuant
hereto in connection with the transactions contemplated hereby shall be deemed to be
representations and warranties by the Company hereunder solely as of the date of such certificate
or instrument. The representations, warranties, covenants and obligations of the Company, and the
rights and remedies that may be exercised by the Purchasers, shall not be limited or otherwise
affected by or as a result of any information furnished to, or any investigation made by or
knowledge of, any of the Purchasers or any of their representatives.

               6.3 Successors and Assigns. Except as otherwise expressly provided herein, the provisions
hereof shall inure to the benefit of, and be binding upon the parties hereto and their respective
successors, assigns, heirs, executors and administrators and shall inure to the benefit of and be
enforceable by each person who shall be a holder of the Shares from time to time; provided,
however, that prior to the receipt by the Company of adequate written notice of the transfer of any
Shares specifying the full name and address of the transferee, the Company may deem and treat the
person listed as the holder of such Shares in its records as the absolute owner and holder of such
Shares for all purposes.

16

 

          6.4 Entire Agreement. This Agreement, the exhibits and schedules hereto, the Related
Agreements and the other documents delivered pursuant hereto constitute the full and entire
understanding and agreement between the parties with regard to the subjects hereof and no party
shall be liable or bound to any other in any manner by any oral or written representations,
warranties, covenants and agreements except as specifically set forth herein and therein. Each
party expressly represents and warrants that it is not relying on any oral or written
representations, warranties, covenants or agreements outside of the Agreement and the Related
Agreements.

          6.5 Severability. In the event one or more of the provisions of this Agreement should, for
any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity,
illegality or unenforceability shall not affect any other provisions of this Agreement, and this
Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been
contained herein.

          6.6 Amendment and Waiver.

               (a) Except as otherwise expressly provided for in Section 2.1(b), this Agreement may be
amended or modified only upon the written consent of the Company and holders of a majority of the
then outstanding Shares (treated as if converted and including any Conversion Shares into which the
then outstanding Shares have been converted that have not been sold to the public).

               (b) The obligations of the Company and the rights of the holders of the Shares and the
Conversion Shares under the Agreement may be waived only with the written consent of the holders of
a majority of the then outstanding Shares (treated as if converted and including any Conversion
Shares into which the then outstanding Shares have been converted that have not been sold to the
public).

          6.7 Delays or Omissions. It is agreed that no delay or omission to exercise any right, power
or remedy accruing to any party, upon any breach, default or noncompliance by another party under
this Agreement, the Related Agreements or the Restated Charter, shall impair any such right, power
or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance,
or any acquiescence therein, or of or in any similar breach, default or noncompliance thereafter
occurring. It is further agreed that any waiver, permit, consent or approval of any kind or
character on any party’s part of any breach, default or noncompliance under this Agreement, the
Related Agreements or under the Restated Charter or any waiver on such party’s part of any
provisions or conditions of the Agreement, the Related Agreements, or the Restated Charter must be
in writing and shall be effective only to the extent specifically set forth in such writing. All
remedies, either under this Agreement, the Related Agreements, the Restated Charter, by law, or
otherwise afforded to any party, shall be cumulative and not alternative.

          6.8 Waiver of Conflicts. Each party to this Agreement acknowledges that Wilson Sonsini
Goodrich & Rosati, Professional Corporation (“WSGR”), outside general counsel to the Company, has
in the past performed and is or may now or in the future represent one or more

17

 

Purchasers or their affiliates in matters unrelated to the transactions contemplated by this
Agreement (the “Financing”), including representation of such Purchasers or their affiliates in
matters of a similar nature to the Financing. The applicable rules of professional conduct require
that WSGR inform the parties hereunder of this representation and obtain their consent. WSGR has
served as outside general counsel to the Company and has negotiated the terms of the Financing
solely on behalf of the Company. The Company and each Purchaser hereby (a) acknowledge that they
have had an opportunity to ask for and have obtained information relevant to such representation,
including disclosure of the reasonably foreseeable adverse consequences of such representation; (b)
acknowledge that with respect to the Financing, WSGR has represented solely the Company, and not
any Purchaser or any stockholder, director or employee of the Company or any Purchaser; and (c)
gives its informed consent to WSGR’s representation of the Company in the Financing.

     [...***...].

          6.9 Notices. All notices required or permitted hereunder shall be in writing and shall be
deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by
confirmed electronic mail, telex or facsimile if sent during normal business hours of the
recipient, if not, then on the next business day, (c) five (5) days after having been sent by
registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after
deposit with a nationally recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the Company at the address as set
forth on the signature page hereof and to Purchaser at the address set forth on Exhibit A
attached hereto or at such other address or electronic mail address as the Company or Purchaser may
designate by ten (10) days advance written notice to the other parties hereto.

          6.10 Expenses. Each party shall pay all costs and expenses that it incurs with respect to the
negotiation, execution, delivery and performance of the Agreement; provided, however, that the
Company shall, at the Closing, reimburse the reasonable fees and expenses of legal

***Confidential Treatment Requested

18

 

counsel to the Purchasers, up to a total of $[...***...],
allocated as follows: (i) up to a total of $[...***...] for other Purchasers, and (ii) up to a total of
$[...***...] for the lead Purchaser.

          6.11 Attorneys’ Fees. In the event that any suit or action is instituted under or in relation
to this Agreement, including without limitation to enforce any provision in this Agreement, the
prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs
and expenses of enforcing any right of such prevailing party under or with respect to this
Agreement, including without limitation, such reasonable fees and expenses of attorneys and
accountants, which shall include, without limitation, all fees, costs and expenses of appeals.

          6.12 Titles and Subtitles. The titles of the sections and subsections of the Agreement are
for convenience of reference only and are not to be considered in construing this Agreement.

          6.13 Counterparts. This Agreement may be executed in any number of counterparts, each of
which shall be an original, but all of which together shall constitute one instrument.

          6.14 Broker’s Fees. Each party hereto represents and warrants that no agent, broker,
investment banker, person or firm acting on behalf of or under the authority of such party hereto
is or will be entitled to any broker’s or finder’s fee or any other commission directly or
indirectly in connection with the transactions contemplated herein. Each party hereto further
agrees to indemnify each other party for any claims, losses or expenses incurred by such other
party as a result of the representation in this Section 6.14 being untrue.

          6.15 Exculpation Among Purchasers. Each Purchaser acknowledges that it is not relying upon
any person, firm, or corporation, other than the Company and its officers and directors, in making
its investment or decision to invest in the Company. Each Purchaser agrees that no Purchaser nor
the respective controlling persons, officers, directors, partners, agents, or employees of any
Purchaser shall be liable to any other Purchaser for any action heretofore or hereafter taken or
omitted to be taken by any of them in connection with the Shares and Conversion Shares.

          6.16 Rights of Purchasers. Each Purchaser, in its sole and absolute discretion, may exercise
or refrain from exercising any rights or privileges that such Purchaser may have pursuant to this
Agreement, the Related Agreements, the Restated Charter, the Company’s Bylaws or at law or in
equity, and such Purchaser shall not incur or be subject to any liability or obligation, any other
Purchaser or holder of Shares, any other stockholder or securityholder of the Company or any other
person, by reason of exercising or refraining from exercising any such rights or privileges,
provided, however that this provision shall not relieve any Purchaser of their voting obligations
pursuant to the Voting Agreement.

          6.17 No Commitment for Additional Financing. The Company acknowledges and agrees that no
Purchaser has made any representation, undertaking, commitment or agreement to provide or assist
the Company in obtaining any financing, investment or other assistance, other than

***Confidential Treatment Requested

19

 

the purchase of the Shares as set forth in Section 1.2 and subject to the conditions set forth
in Section 5.1. In addition, the Company acknowledges and agrees that (i) no statements, whether
written or oral, made by any Purchaser or its representatives on or prior to the date hereof shall
have created an obligation, commitment or agreement to provide or assist the Company in obtaining
any financing or investment, (ii) the Company shall not rely on any such statement by any Purchaser
or its representatives and (iii) an obligation, commitment or agreement to provide or assist the
Company in obtaining any financing or investment may only be created by a written agreement, signed
by such Purchaser and the Company, setting forth the terms and conditions of such financing or
investment and stating that the parties intend for such writing to be a binding obligation or
agreement. Absent a written agreement to the contrary, signed by such Purchaser, such Purchaser
shall have the right in its sole and absolute discretion, to refuse or decline to participate in
any other financing of or investment in the Company, and shall have no obligation to assist or
cooperate with the Company in obtaining any financing, investment or other assistance.

          6.18 Pronouns. All pronouns contained herein, and any variations thereof, shall be deemed to
refer to the masculine, feminine or neutral, singular or plural, as to the identity of the parties
hereto may require.

          6.19 California Corporate Securities Law. THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF
THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF
CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE
CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION OR IN THE ABSENCE OF AN EXEMPTION FROM SUCH
QUALIFICATION IS UNLAWFUL. PRIOR TO ACCEPTANCE OF SUCH CONSIDERATION BY THE COMPANY, THE RIGHTS OF
ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED OR
AN EXEMPTION FROM SUCH QUALIFICATION BEING AVAILABLE.

[THIS SPACE INTENTIONALLY LEFT BLANK]

20

 

     IN WITNESS WHEREOF, the parties hereto have executed the SERIES F PREFERRED STOCK PURCHASE
AGREEMENT as of the date set forth in the first paragraph hereof.

	 	 	 	 	 
	 	COMPANY:

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

 	 
	 	By:  	/s/ Hugh Martin
 	 
	 	Name:  	Hugh Martin 	 
	 	Title:  	Chief Executive Officer	 
	 
	 	Address:	
             1505 Adams Drive

Menlo Park, CA  94025 	 
	 

 

 

     IN WITNESS WHEREOF, the parties hereto have executed the SERIES F PREFERRED STOCK PURCHASE
AGREEMENT as of the date set forth in the first paragraph hereof.

	 	 	 	 	 
	 	PURCHASERS:

GEN-PROBE INCORPORATED

 	 
	 	By:  	/s/ Eric Tardif
 	 
	 	Name:  	Eric Tardif 	 
	 	Title:  	SVP, Corporate Strategy

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}]]